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Introduction 
Thrombosis is the term used for pathological formation of blood clots in the 
venous or arterial vasculature. Self-limited clot formation prevents excessive 
blood loss and illustrates the natural response to vascular injury. Pathologic 
clot formation (thrombosis) can represent itself in arterial vessels as arterial 
thrombosis or in venous vasculature as venous thrombosis.  
The hemostatic system includes several major components that regulate the 
process of clot formation: vascular endothelium, procoagulant plasma protein 
factors, platelets, anticoagulant proteins, fibrinolytic proteins and antifibrinolytic 
proteins. All these factors need to be present adequately to regulate clot 
formation in a way that clots can be formed when needed but excessive clot 
formation will be prevented.  
Venous thrombosis is a common disease. It affects 1-2 individuals per 1000 
each year. The incidence is age-related with an increasing incidence by age. 
Venous thrombosis mostly presents itself as deep vein thrombosis in the legs 
or pulmonary embolism. Less frequent localizations of venous thrombosis are 
cerebral veins, arm veins, mesenterical veins and Budd-Chiari syndrome due 
to thrombosis in the liver veins. The pathophysiology of venous thrombosis is 
considered to be multicausal1. Well- known clinical factors associated with 
venous thrombosis are pregnancy, malignant disease, prolonged bed rest and 
major surgery. Over the years several factors have been discovered that 
contribute to venous thrombosis, both inherited (i.e., Antithrombin deficiency, 
Protein S or C deficiency) and acquired factors. In the past few years several 
new risk factors were identified. These include Factor V Leiden, high levels of 
clotting factor VIII, IX or XI, fibrinogen and the presence of lupus anticoagulant 
(in combination with anti Beta2-glycoprotein I antibodies)2,3. A reduced activity 
of the fibrinolytic potential may also be associated with venous thrombosis4. A 
combination of clinical factors and clotting abnormalities may further increase 
the risk for venous thrombosis such as cancer in combination with factor V 
Leiden or the prothrombin 20210A mutation5. Interestingly, factors that are 
associated with a first event of venous thrombosis appear not invariably 
associated with recurrent venous thrombosis6. 
Another recently identified risk factor is mild hyperhomocysteinemia. The 
amino-acid homocysteine was described in the early 1960s and found in high 
concentrations in the urine of children with ‘homocystinuria’ (i.e., high 
concentrations of homocystine, a disulfide of homocysteine, in the urine)7. 
Classic homocystinuria is an ‘inborn error of metabolism’, caused by a 
homozygous deficiency of the enzyme cystathionine-β-synthase, an enzyme 
involved in the transsulphuration of homocysteine to cysteine. Patients with this 
disease suffer from ectopia lentis, a Marfanoid posture, mental retardation and 
osteoporosis. Additionally, in the second and third decade of life, they have a 
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risk of 40 to 50% percent of developing arterial and venous thrombosis. This 
high incidence of vascular disease led to the hypothesis that high 
homocysteine concentrations due to decreased activity of cystathionine-β-
synthase might be involved in the pathogenesis of vascular disease in 
individuals not affected with homocystinuria. It was first suggested that the 
activity of cystathionine-β-synthase was decreased in patients with arterial 
vascular disease8,9. In later studies this finding could not be reproduced10,11. 
Moreover, carriers of the mutation in the cystathionine-β-synthase gene did not 
have an increased risk for developing vascular disease. Nevertheless, 
homocysteine levels were elevated in patients with vascular disease in 
comparison with those without vascular disease, as was observed in case-
control studies and prospective investigations. These studies mostly confirmed 
the hypothesis that homocysteine is associated with arterial vascular 
disease12,13. 
We were among the first to describe an association between venous 
thrombosis and hyperhomocysteinemia in patients with recurrent venous 
thrombosis14, and subsequently demonstrated an increased risk for a first 
deepvenous thrombosis in the so-called Leiden Thrombophilia Study15. A 
recent meta-analysis confirmed the association between hyperhomo-
cysteinemia and venous thrombosis in both case-control studies and 
prospective studies16.  
 
This thesis focuses on the relation between plasma homocysteine levels and 
venous thrombosis and deals with several aspects of this relation. The main 
investigation in this thesis is based on two starting points.  
First, hyperhomocysteinemia is associated with venous thrombosis but a 
causal relationship has not been proven. Observational studies may have 
showed associations that were either the result of thombosis having an effect 
on homocysteine levels when blood samples are taken after the event, or arise 
from a true cause of thrombosis also affecting homocysteine levels. The 
second starting point is that homocysteine can be easily lowered. A 
combination of folic acid, a synthetic form of folate, hydroxycobalamin and 
pyridoxine decreases homocysteine concentrations by approximately 35% in 
both thrombosis patients and healthy persons with hyperhomocysteinemia, but 
also by 20-30% in patients and healthy persons with normal homocysteine 
plasma concentrations17.  
These two points lead to the possibility of an experimental approach to the 
causality of the association: If homocysteine-lowering prevents thrombosis, 
hyperhomocysteinemia is likely to indeed be causally linked to thrombosis. This 
would of course be of much wider relevance than just for etiology, and be of 
great interest to patients and clinicians since homocysteine is a prevalent risk 
factor and such therapy, if efficacious, has been estimated to be able to 
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prevent as much as 25% of events. Furthermore, vitamin therapy is probably 
safe. 
The experimental approach was a randomized and placebo-controlled 
secondary prevention trial with high-dose B-vitamins in patients with a primary, 
idiopathic venous thrombosis and hyperhomocysteinemia (chapter 2 and 8). 
 
Two studies in this thesis deal with laboratory aspects of plasma homocysteine. 
Blood collection for determination of the homocysteine concentration should be 
performed meticulously and stored at 0°C before separation of the plasma to 
prevent ongoing synthesis of homocysteine ex vivo18. Since this was not 
feasible in the setting of a multicentre trial, we sought a blood collection tube 
which stabilizes the blood at room temperature. This led to two investigations: 
first, we tested the stability of homocysteine in acidic citrated tubes (chapter 3). 
In previous (unpublished) studies it was made likely that acidic citrate might 
have this stabilizing effect. The second study was based on the results of the 
first study where we found a difference in baseline homocysteine 
concentrations measured in acidic citrate plasma in comparison to EDTA 
plasma. Measurement of homocysteine in EDTA plasma is considered to be 
the gold standard. We therefore compared the measurement of homocysteine 
in acidic citrate with the measurement in EDTA more extensively and used 
different measurement methods to explore differences between these methods 
(chapter 4). 
The study described in chapter 5 deals with the effect of oral anticoagulants on 
homocysteine concentrations. Many studies in venous thrombosis have been 
performed with patients who were treated with anticoagulant therapy. If 
coumarin derivates have an effect on homocysteine concentrations, the results 
of those studies may have been flawed. Such an observation might therefore 
be relevant for an adequate interpretation of homocysteine values for patients 
using anticoagulant drugs both in epidemiological studies as well as for 
individual risk estimation. We performed a follow-up study with patients who 
were going to be treated with anticoagulants after orthopedic surgery and 
measured homocysteine concentrations before, during and after the treatment 
period. We also estimated the potential error in previous studies that included 
such patients. In addition we studied the influence of anticoagulants on 
homocysteine levels in a group of healthy individuals. (chapter 5).  
Another aspect of the relation between homocysteine and venous thrombosis 
is the pathophysiological mechanism by which hyperhomocysteinemia leads to 
the development of a thrombus. Several mechanisms have been proposed in 
the literature19-28. We investigated the influence of homocysteine on the 
coagulation pathway by means of the endogenous thrombin potential (ETP). 
The ETP reflects the capacity to generate thrombin and is elevated in patients 
with prothrombotic conditions, such as factor V Leiden, antithrombin deficiency 
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and oral contraceptive use29,30. We compared the endogenous thrombin 
potential in patients with hyperhomocysteinemia and normohomocysteinemia 
(chapter 6). 
During the screening of patients for the intervention trial (chapter 8) we noticed 
high homocysteine concentrations in elderly patients. Homocysteine 
concentrations increase exponentially with increasing age31, and so does the 
incidence of thrombosis32. Little is known about the risk of thrombosis of elderly 
people with hyperhomocysteinemia. If hyperhomocysteinemia is a cause of 
thrombosis, homocysteine-lowering therapy could have a great effect, 
especially in this age group where hyperhomocysteinemia and thrombosis are 
frequent. We designed a case-control study including elderly patients with an 
idiopathic thrombosis and healthy controls, selected from general practices 
(chapter 7).  
In the general discussion (chapter 9) we summarize our studies, with emphasis 
on the therapeutic options in hyperhomocysteinemia and venous thrombosis.  
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In the past years several case-control studies established the association of an elevated plasma 
homocysteine concentration and the risk of venous thromboembolism. It is still unclear if elevated 
homocysteine concentrations can cause venous thrombosis. The VITRO (VItamins and 
ThROmbosis) trial is the first multicenter, randomized, doubleblind and placebo-controlled study to 
evaluate the effect of homocysteine-lowering therapy by means of 5 mg folic acid, 0.4 mg vitamin 
B12 and 50 mg vitamin B6. The study is a secondary prevention trial in 600 patients who suffered 
from a first episode of idiopathic deep vein thrombosis (DVT) or pulmonary embolism (PE), or both. 
There will be 300 hyperhomocysteinemic and 300 normohomocysteinemic patients included, all 
with an objectivated venous thrombosis. The end point is recurrence of venous thrombosis. 
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Introduction 
Venous thromboembolism is a common illness with an incidence of 1 to 2 per 
1000 per year1,2. Common causes of venous thromboembolism are acquired 
factors (cancer, immobility, fractures of the leg, knee or hip operations and use 
of oral contraceptives) or hereditary factors (deficiencies of protein C, protein S, 
and antithrombin3, high levels of Factor VIII4, mutations in the Factor II gene5 
and in the Factor V gene resulting in activated protein C resistance6). In the 
past two decades much emphasis has been laid on the role of mild hyperhomo-
cysteinemia as a possible risk factor of venous as well as arterial thrombo-
embolism. In this article we will discuss the association of hyperhomo-
cysteinemia and venous thrombosis, and we will give the design of the VITRO 
study, a secondary prevention study on the effect of homocysteine-lowering 
therapy on recurrence of venous thrombosis. 
Homocysteine and venous thrombosis 
Given the high incidence of arterial thrombotic disease in patients with classic 
homocystinuria, Wilcken and Wilcken7 investigated the association of 
homocysteine and arterial thrombotic disease in patients with premature 
arterial disease. The association they found was later confirmed by a number 
of retrospective and prospective studies8. These studies established hyper-
homocysteinemia as a possible risk factor for arterial thrombotic disease. 
Hwever, patients with homocystinuria are afflicted not only by arterial 
thrombosis but also by venous thromboembolism (VTE). By analogy to the 
hypothesis of Wilcken and Wilcken7 in arterial disease, several studies have 
been performed since 1991 to investigate the association of homocysteine and 
venous thrombotic disease. The epidemiological evidence of homocysteine as 
a risk factor for venous thrombosis, however, is not as abundant as for arterial 
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Retrospective Studies 
In 1991 Brattstrom et al.9 published a study in which average homocysteine 
concentrations did not differ between patients with VTE and controls. Patients, 
however, had an elevated level more often, although it was not significant 
because of low sample size. Bienvenu et al.10 in 1993 found a distinct 
difference in homocysteine concentrations between patients with either arterial 
or venous thrombosis and healthy controls. This finding was confirmed by 
Falcon et al.11 Our group published a study in 1995: fasting and post-
methionine homocysteine concentrations of 185 patients with a history of 
recurrent VTE and 220 controls from a general practice were compared12. 
Odds ratios of 3.1 were found for both preload and postload homocysteine 
concentrations above the 90th percentile of the control group (18.6 µmol/l). An 
increase of the risk was already seen at homocysteine concentrations of 
14.0 µmol/l. A second study was performed to estimate the risk of 
homocysteine for a first episode of VTE. Homocysteine concentrations of a 
subgroup of patients participating in the Leiden Thrombophilia Study were 
analyzed13. All patients had had a first, objectively confirmed DVT. Baseline but 
no postload homocysteine levels were available. An odds ratio of 2.5 was 
calculated for homocysteine concentrations above the 95th percentile of the 
control group. Also, in this group the odds ratios increased with higher cut-off 
concentrations. The effect was independent from known hereditary risk factors 
for VTE such as protein C, protein S, or antithrombin deficiency and, 
unexplainably, more pronounced in women than in men. No interrelation 
between Factor V Leiden and hyperhomocysteinemia could be established as 
a result of the small number of subjects with both abnormilities. 
More case-control studies were published subsequently that confirmed the 
association of hyperhomocysteinemia and venous thrombosis14-17. 
Prospective Studies 
Only two prospective studies have been published so far. The U.S. Physicians 
Health Study is a prospective cohort study in male physicians18. Homocysteine 
concentrations were determined in 14,916 men at baseline. From these men 
158 developed a venous thrombosis during the subsequent follow-up years 
(mean, 12 years). These cases were matched with 646 controls from the same 
cohort. When analyzing all VTE cases with controls, the investigators found no 
association between an elevated homocysteine concentration and VTE. 
However, when only the cases who had suffered an idiopathic VTE were 
analyzed, they found a relative risk of 3.4. Furthermore, this study 
demonstrated an even more increased risk of VTE when both hyperhomo-
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cysteinemia and Factor V Leiden were present, suggesting a synergy. Also, 
this finding was more pronounced when only idiopathic cases of VTE were 
analyzed. 
A second prospective study was performed by Eichinger et al.19 They selected 
patients with a first episode of idiopathic VTE. After the event total 
homocysteine (tHcy) was measured. Patients were followed for recurrence of 
VTE. Hyperhomocysteinemic patients were found to be at greater risk for 
recurrence than were the normohomocysteinemic patients. This resulted in a 
relative risk of 2.6 when corrected for age, sex, and the presence of Factor V 
Leiden. 
In a meta-analysis of 10 published case-control studies on the risk of 
hyperhomocysteinemia and venous thrombosis, pooled estimates of the odds 
ratios were calculated20. The authors found odds ratios of 2.5 (95% confidence 
interval (CI) 1.8 to 3.5) for fasting levels and 2.6 (95% CI 1.6 to 4.4) for 
postmethionine increased concentrations, supporting the hypothesis that 
hyperhomocysteinemia is a risk factor for venous thromboembolism. 
As yet there is no clear evidence how hyperhomocysteinemia could lead to 
venous thrombosis. How hyperhomocysteinemia might cause thrombosis is 
subject of a different article in this issue. 
Therapy of hyperhomocysteinemia 
Folic acid, hydroxycobalamin (vitamin B12), and pyridoxine (vitamin B6) form 
the key elements in the therapy of hyperhomocysteinemia. These vitamins 
function as cosubstrate or as cofactor in the metabolic pathways of 
homocysteine. High-dose pyridoxine, which as pyridoxal-‘5-phosphate acts as 
cofactor with cystathionine beta-synthase (CS) in the transsulphuration 
pathway, is the vitamin that is used in the treatment of classical 
homocysteinuria. Therapy with pyridoxine is suggested to decrease the 
incidence of vascular complications in these patients21,22. A meta-analysis of 10 
studies by the Homocysteine Trialists’ Collaborators showed that in mild 
hyperhomocysteinemia folic acid is the main homocysteinelowering vitamin23: 
0.5 to 5 mg of folic acid daily reduced homocysteine concentrations by about 
25%. An extra 7% decrease was produced by 0.5 mg/d of vitamin B12. Not 
only elevated levels of homocysteine but also concentrations usually regarded 
as normal (<16 µmol/l) were decreased by vitamin supplementation24. Similar 
decreases were found in patients with venous thrombosis as in controls24. 
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VITRO study 
Study rationale 
The clinical key question is whether a decrease of homocysteine 
concentrations will prevent thromboembolic events25.This is a question that 
needs to be answered: It will make us understand more about homocysteine as 
a possible causal agent of thromboembolic disorders, and it could have great 
impact on the prevention of vascular diseases8. (Although homocysteine is not 
a strong risk factor, it is, when defined as levels above the 75th or 90th 
percentile, a very prevalent one.) 
In order to answer this question, intervention studies are needed. These 
studies should be randomized and placebo controlled and therefore not 
susceptible to bias or confounding factors such as vitamin supplementation or 
changing dietary habits that can easily influence homocysteine levels. Some 
investigators argue the need for randomized trials because a substantial 
amount of evidence is available from retrospective and prospective studies and 
vitamin therapy appears to be safe. However, every therapeutic intervention 
deserves a proper evaluation before it is used on a broad scale. Furthermore, 
although vitamin therapy appears to be safe, the risk of unsuspected adverse 
effects should be taken into account in every intervention. 
In 1996 the VITRO trial was started in the Netherlands. The VITRO trial is a 
study on the effect of vitamin B in the secondary prevention of venous 
thrombosis. It is a multicenter, randomized, double-blind and placebocontrolled 
trial. The study is a collaborative project of the Department of Hematology of 
the Leyenburg Hospital in The Hague, the Department of Clinical Epidemiology 
of the Leiden University Hospital, the Laboratory of Pediatrics and Neurology of 
the Nijmegen University Hospital, and the anticoagulation clinics of The Hague, 
Rotterdam, Amsterdam, Utrecht, Leiden, Amersfoort, and Delft, The 
Netherlands. Furthermore, there are four participating centers outside the 
Netherlands: in Vienna, Austria, and in Milano, Bolzano, and Bologna, Italy. 
Study objective 
The trial was designed to evaluate whether the effect of homocysteine-lowering 
therapy by means of multivitamin B in patients with a primary venous 
thromboembolism and hyperhomocysteinemia leads to a reduction of recurrent 
thrombosis. 
Patient selection 
In the Netherlands almost all patients treated with oral anticoagulants are 
registered at anticoagulation clinics after hospital discharge or directly after 
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diagnosis when treated in an outpatient setting. The anticoagulation clinics 
monitor the treatment by international normalized ratio (INR) measurements 
and adjust the dose of the coumarins. Patients are recruited for the VITRO 
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Figure 2.1  VITRO trial: patient selection and randomization. 
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All new patients registered with the diagnosis of primary DVT or PE are asked 
to donate an extra blood sample for measurement of their homocysteine 
concentration. The previously mentioned centers cover a well-defined 
geographical area of about 3.5 million people in the Netherlands. Because 
these centers treat nearly all patients with venous thrombosis, the VITRO study 
is able to include patients without substantial referral bias. The blood is 
sampled in tubes containing acidic citrate as anticoagulant. In these tubes the 
blood is stabilized at room temperature for measurement of the homocysteine 
concentrations26. Homocysteine values measured in these tubes correlate very 
well with those measured in classically used tubes, in other words, tubes 
containing ethylenediaminetetracetic acid (EDTA) as anticoagulant, that are put 
the plasma is sent to Nijmegen for determination of the homocysteine by 
regular mail because plasma samples stay stable for several days at room 
temperature27. In the meantime, information is retrieved from the patients’ 
general practitioner or specialist about the diagnosis and circumstances in 
which the patients developed their thrombosis. Once patients have met all 
entry criteria, they are asked to participate in the study 1 month before the 
treatment with the coumarins is terminated. In this month a substantial 
homocysteine decrease can be achieved23. Patients have to give their informed 
consent in accordance with the current revision of the declaration of Helsinki 
(1975) in order to participate in the study. 
Hyperhomocysteinemic and normohomocysteinemic groups 
Two groups of patients are recruited for the VITRO study: a group of patients 
with hyperhomocysteinemia and a group of similar size with patients with 
normohomocysteinemia. Because the number of patients with normohomo-
cysteinemia presented by the anticoagulation clinics is greater than the number 
with hyperhomocysteinemia, a random selection of all normohomocysteinemic 
patients is made in order to achieve a parallel inclusion: one normo-
homocysteinemic patient for every hyperhomocysteinemic patient included. 
Entry criteria 
1. Objectively confirmed, primary, proximal DVT (diagnosed with compression 
ultrasonography or venography) or PE (diagnosed with “high probability” 
ventilation-perfusion [V/Q] scanning or pulmonary angiography), or both 
2. Homocysteine concentrations above the 75th percentile of a reference 
group of the general population from which the patients are selected 
(hyperhomocysteinemic group) or homocysteine concentrations below the 
75th percentile of this reference group (normohomocysteinemic group) 
al., unpublished data). The blood is processed in the anticoagulation clinic and 
on melting ice immediately after blood collection until processing (Willems et 
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3. Age 20 to 80 years 
4. Absence of other major risk factors for DVT such as major abdominal 
surgery, major hip and knee operations, fractures of the legs or hips, 
multitrauma, malignant disease, pregnancy and childbirth, paralysis of the 
legs, immobility for more than 3 weeks  
5. Ability to start the study at least 4 weeks before discontinuation of the 
coumarins in order to ensure substantial homocysteine decrease at that 
time Patients with the following conditions are excluded: (obligatory) use of 
vitamin B, continued use of coumarins, pregnancy or trying to get pregnant, 
and the use of medications that are influenced by folic acid (phenytoin, 
L-dopa, methotrexate). 
Randomization 
Randomization is done by someone not involved in the treatment of the 
patients. The randomization is stratified by gender and by anticoagulation 
clinic. Randomization tables with six and four random permuted blocks are 
used for the randomization.  
Treatment schedule and trial medication 
The treatment group will be treated with 1 capsule daily containing 5 mg folic 
acid, 400 µg hydroxycobalamin, and 50 mg pyridoxine. The stability of this 
combination has been tested and proven valid for the duration of the study. The 
placebo group will take 1 placebo capsule daily. The study medication is 
provided by Dagra Farma, Amsterdam, The Netherlands. 
Follow-up 
Randomized patients are seen at outpatient clinics at the start of the study and 
3, 6, and 24 months after randomization. Because the time span between the 
follow up visits to the outpatient clinics is quite large, patients will be 
interviewed by telephone every 6 months. The duration of the study for each 
patient is 2.5 years. Because the last visit to the outpatient clinic is already after 
2 years, the trial will end for each patient after an interview 
by telephone. At each follow-up visit blood is sampled for determination of 
tHcy. By means of determination of tHcy, therapy compliance is measured. 
Patients are seen after overnight fasting. Patients receive their study 
medication at these follow-up visits, and the leftover capsules will be taken 
back. 
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Ultrasonographies 
In patients with DVT of the leg, a compression ultrasonography (cUS) is 
performed 3 months after the thrombosis. The cUS is done to enhance the 
diagnosis of a possible recurrence. If residue of the old thrombus is seen on 
the cUS, the cUS is repeated 6 and, if necessary, 12 months after the 
thrombosis. In patients with a PE, a cUS of both legs is performed to exclude a 
DVT. The ultrasonographies are performed in one hospital or institution in 
every participating city. The results of the cUS are noted in a so-called patient 
passport, a booklet that patients are instructed to give to the physician if signs 
and symptoms of a thrombosis recur. By using this passport, the data on the 
residual thrombosis are available, even if patients visit other hospitals. The 
diagnosis “recurrent DVT” can be made when a previously normal or 
normalized venous segment cannot be compressed or when there is an 
increase in the diameter of residual thrombus by 4 mm28,29. 
Endpoint 
Endpoint in the study is recurrent DVT or recurrent PE, or both, as diagnosed 
by the treating physician and scored definitive if anticoagulants are prescibed. 
The diagnosis might be confirmed by using objective tests as described before. 
Analysis will be done on the confirmed and nonconfirmed (but indicating clinical 
relevance) recurrent events and on the confirmed recurrences only. 
Study size 
The study size is calculated for the hyperhomocysteinemic group. With α=0.05 
and β=0.2 and with a recurrence percentage of 20% in the placebo group and 
a 50% risk reduction because of the vitamin therapy, 155 patients in each 
treatment group are required if tested one sided. This means that more than 
310 patients will be randomized. A similar number of patients will be included in 
the normohomocysteinemic group, resulting in a total study size of 620 
patients. 
Possible outcome and outlook 
For the VITRO study only patients with an idiopathic venous thrombosis are 
selected. It is hypothesized that these patients have no apparent cause of their 
thrombosis; therefore, the contribution of homocysteine in the etiology of the 
thrombosis might be greater than in patients with very apparent causes such as 
bedrest, hip fractures, and so on. This hypothesis was later confirmed by the 
results of the study by Ridker et al 18, which showed a higher odds ratio in 
idiopathic thrombosis than it did in nonidiopathic thrombosis. A second 
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assumption is that patients with idiopathic DVT or PE are at higher risk for 
recurrent thrombosis in comparison with patients with an environmental and 
reversible cause 30. Based on the results of the case-control studies, 
homocysteine is a risk factor for venous thrombosis. However, it is not a 
certainty that lowering homocysteine concentrations will have an effect on 
recurrence of events. Most case-control studies are retrospective and do not 
address the issue of causality; they only show associations. It could be 
hypothesized that homocysteine is a result of the thrombosis, in which case 
homocysteinelowering therapy will not result in a decrease in the number of 
recurrent events. However, from the results of the two prospective studies, this 
is not likely. Another, more likely assumption is that the homocysteine increase 
is an epiphenomenon: an unknown disorder leading to thrombosis as well as to 
homocysteine increment. If homocysteine is such an epiphenomenon, 
prospective case-control studies will show an association, but homocysteine-
lowering therapy will not take away the causal agent of the thrombosis and 
intervention will not result in a decease of recurrent events. Even if 
homocysteine is a causal agent in the development of venous thrombosis, the 
effect of homocysteine- lowering therapy on recurrent thrombosis can only be 
assumed. Only two of the previously discussed studies address the association 
of homocysteine and recurrent thrombosis. The study by den Heijer et al. 12 on 
recurrent thrombosis shows an odds ratio that is very much in the range of the 
odds ratios found in studies on primary thrombosis. One could conclude that 
homocysteine is a risk factor only for primary thrombosis and not a risk factor 
for recurrence any more when patients have already had their first thrombotic 
event. Other risk factors, for instance an insufficient venous system caused by 
the first thrombosis, then play a much more important role that diminishes a 
possible effect of homocysteine. 
Lowering homocysteine concentrations would not make a great difference or 
would even be useless. The study by Eichinger et al.19 however, estimated the 
risk of recurrent thrombosis compared with patients who already had a first 
thrombotic event and showed an odds ratio of 2.7, supporting the hypothesis 
that homocysteine-lowering therapy could have an effect on recurrent 
thrombosis.  
In this study two groups of patients were selected, a hyperhomocysteinemic 
and a normohomocysteinemic group. Based on the results of case-control 
studies, the risk of disease in this latter group is lower than it is in the 
hyperhomocysteinemic group 12,13,19.The addition of a normohomocysteinemic 
group can provide us with important extra information. Four types of outcome 
can be hypothesized. 
1. There is no effect of vitamin therapy on recurrence in both groups. This 
outcome hypothesis is discussed earlier. 
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2. Vitamin therapy will only have an effect in the hyperhomocysteinemic group, 
suggesting that hyperhomocysteinemia above a certain concentration is a 
causal agent in the development of venous thrombosis. 
3. Vitamin therapy will have a similar effect in both the hyperhomocysteinemic 
and the normohomocysteinemic group, suggesting a pathophysiological 
mechanism that acts independent of homocysteine (e.g., folic acid mediated). 
4. The effect of vitamin therapy is greater in the hyperhomocysteinemic group 
than it is in the normohomocysteinemic group. This suggests a graded 
association of homocysteine and venous thrombosis: The effect of vitamins will 
be more pronounced in patients with higher levels of homocysteine. Because 
vitamin therapy causes homocysteine decrease, even of previous “normal” 
concentrations24 effect of vitamins on recurrence of thrombosis in the 
normohomocysteinemic group cannot be ruled out. Although there are not 
sufficient data from the case-control studies done in venous thrombosis, 
studies in arterial vascular disease suggest such a graded response8. Based 
on the results from the hyperhomocysteinemic group, trend analyses will be 
performed in the VITRO study to measure the effect in the 
normohomocysteinemic group. 
In 1996, the trial was started in The Netherlands. In 1998, the four centers 
outside The Netherlands were approached for participation and started 
randomizing patients. These centers are provided with the same study 
medication and randomize patients according to the same entry criteria. 
Homocysteine measurements are done in each respective center and the cut-
off level of the homocysteine is based on the 75th percentile of the local 
reference group. By July 1999, more than 500 patients were randomized. The 
study is expected to be complete in the beginning of 2000. Results of the study 
can be expected by the end of 2002. 
If homocysteine lowering effectively decreases the number of recurrent venous 
thromboembolic events, this will be of great benefit for patients. It will not only 
reduce the risk of recurrence but also diminish morbidity and mortality resulting 
from the use of long-term anticoagulant therapy in patients after a second 
event. In addition, if vitamin treatment will reduce the number of events it will 
prove the relevance of homocysteine metabolism as a risk factor in vascular 
disease, a conclusion impossible to make from case-control studies and still a 
subject of debate in the prospective studies. 
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Introduction 
Homocysteine is a sulfhydryl-containing amino acid, formed by demethylation 
of the essential amino acid methionine. Homocysteine is either transsulfurated 
to cysteine or is remethylated to methionine by methionine synthase. Excess 
intracellular homocysteine is likely to be transported to the extracellular 
compartment1. Increasing evidence indicates that homocysteine is implicated in 
the pathogenesis of thromboembolic diseases. Several case control studies 
have shown a relationship between increased total plasma homocysteine 
(tHcy) concentrations and an increased risk of arterial2-4 and venous 
thrombosis5–8. An increase of the tHcy concentration of 5 µmol/l is associated 
with 1.5–1.9 times increased risk for coronary artery or cerebrovascular 
disease9.These values indicate that small differences may be of clinical 
importance. Therefore, practical standardized conditions for handling blood 
specimens for tHcy determination are required. In most studies, blood is drawn 
in tubes containing K3EDTA. The whole-blood sample is immediately put on 
crushed ice and then centrifuged as soon as possible to prevent an increase of 
tHcy concentrations. This tHcy increase is caused by ongoing homocysteine 
metabolism in blood cells, the majority of which are red blood cells10,11. This 
blood handling procedure is not practical, particularly when larger studies are 
conducted outside a hospital setting; even in a routine clinical setting, this 
protocol might be hard to put into practice. To find an alternative, more suitable 
blood-collection medium, we investigated the effect of different blood-collection 
media on tHcy production when whole blood is kept at room temperature for 6 
hours. 
Methods 
Blood was drawn by venipuncture of the antecubital vein from laboratory 
coworkers or from consecutive patients who visited the outpatient clinics of the 
Leyenburg Hospital in The Hague for various reasons, unknown to the authors. 
Informed consent was obtained in accordance with the current revision of the 
Helsinki declaration of 1975. Two studies were performed. A pilot study was 
done with blood from 11 patients and 11 laboratory coworkers (12 men and 10 
women; ages 18–63 years). Blood was drawn in tubes with 1.8 g/l K3EDTA 
(Vacutainer Tube; Becton Dickinson), in tubes with 2.5 g/l sodium fluoride and 
2 g/l potassium oxalate as anticoagulant (Vacutainer Tube), in tubes with 
0.5 mol/l acidic citrate (Biopool StabilyteTM), and in tubes with a mixture of the 
sodium fluoride, potassium oxalate, and acidic citrate. Care was taken that all 
tubes were completely filled by blood. The EDTA-treated blood was put on 
crushed ice immediately after venipuncture. The other blood samples were 
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kept at room temperature. The results of this pilot study indicated that tHcy 
concentrations remained stable in acidic citrate. We conducted a second study 
to explore this phenomenon more extensively. This main study was done in 30 
laboratory coworkers (17 men and 13 women; ages 18–52). Blood was taken in 
tubes with EDTA and acidic citrate (as described above). From every volunteer, 
one-half volumes of the tubes containing EDTA were kept at room temperature; 
the other half were put on crushed ice immediately after sampling. From the 
tubes with acidic citrate, one-half volumes were kept at room temperature, and 
the other half were stored in water of 37°C. In both study groups, the blood was 
centrifuged for 10 min at 2000g as soon as possible (within 15 min) after 
sampling (“0 h”) and 2, 4, and 6 h after the venipuncture. 
After separation, the plasma was stored at -20°C until determination of the 
tHCy concentration at the Laboratory of Pediatrics and Neurology of the 
University Hospital Nijmegen (by H.J.B. and S.V.) by automated HPLC with 
reversed-phase separation and fluorescent detection [Gilson 232–401 sample 
processor (Gilson Medical Electronics, Inc.), Spectra-Physics 8800 solvent 
delivery system, and Spectra-Physics LC 304 fluorometer], according to the 
method described by Fiskerstrand et al.12 with some modifications13. The tHcy 
concentrations from the tubes containing the acidic citrate were corrected for 
the dilution caused by the fluid already present in the tube before blood 
collection.  
Paired-sample t-tests were used to calculate the significance of the increase of 
tHcy concentrations in the collection media. Paired-sample t-tests were also 
used to calculate the significance of the differences between the tHcy 
concentrations in the different collection media at baseline. Results of the 
t-tests are given as the intervals that show P<0.05 significance [95% 
confidence intervals (CI)]. 
Results 
Results of the pilot study are shown in Table 3.1. tHcy concentrations in blood 
taken in tubes containing sodium fluoride rose markedly after 2 h (0.9 µmol/l; 
95% CI 0.5 to 1.3 µmol/l). In the tubes containing sodium fluoride with acidic 
citrate, tHcy concentrations remained stable for 4 h. After 6 h, there was a 
slight increase of 0.6 µmol/l (95% CI 0.0 to 1.1 µmol/l). tHcy concentrations in 
blood taken in tubes containing EDTA that were stored at 0°C and tHcy 
concentrations taken in tubes with acidic citrate that were kept at 21°C did not 
rise markedly for 6 h [0.0 µmol/l (95% CI -0.5 to 0.6 µmol/l) and 0.4 µmol/l (95% 
CI -0.5 to 0.9 µmol/l), respectively]. Results of the main study are shown in 
Figure 3.1 and in Table 3.1. tHcy concentrations in the EDTA-containing tubes 
that were put on ice did not rise markedly for 6 h (0.3 µmol/l; 95% CI -0.1 to 
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0.7 µmol/l). tHcy concentrations in the EDTA-containing tubes that were stored 
at room temperature rose 2.0 µmol/l after 2 h (95% CI 1.6 to 2.4 µmol/l) and up 
to 4.7 µmol/l (95% CI 4.1 to 5.3 µmol/l) after 6 h. At room temperature, the tHcy 
concentrations in acidic citrate did not rise markedly for 6 h after collection 
(0.3 µmol/l; 95% CI -0.2 to 0.7 µmol/l), whereas tHcy concentrations in blood 
collected in acidic citrate stored at 37°C increased markedly after 4 h 
(0.9 µmol/l; 95% CI 0.5 to 1.3 µmol/l).  
We found a difference of 1.3 µmol/l (95% CI 0.9 to 1.6 µmol/l) between tHcy 
concentrations measured in blood sampled in tubes with EDTA and stored at 
0°C and tHcy concentrations measured in blood sampled in tubes with acidic 
citrate kept at room temperature. Such significant differences were present at 
all measurement times. When the results of the pilot study and the main study 
were combined, this difference decreased but was still significant (0.8 µmol/l; 
95% CI 0.4–1.1 µmol/l; range, -3.1 to 2.2 µmol/l). 
 
Table 3.1 Mean (±SD) increase in homocysteine (in µmol/l) in whole blood in different collection 
media. 
   Pilot study (n=22)  Main study (n=30) 
    Increase after   Increase after 
Storage medium Temp. 
°C 
 Baseline 2 h 4 h 6 h  Baseline 2 h 4 h 6 h 
EDTA 0  12.5 (2.4) 0.1 (1.1)  0.4 (0.9) 0.1 (1.2)  12.7 (3.3) 0.1 (1.3) 0.1 (1.3) 0.3 (1.1) 
Acidic citrate 21  12.6 (2.6) 0.1 (1.1)  0.4 (0.8) 0.4 (1.1)  14.0 (3.6) 0.0 (1.1) 0.0 (1.1) 0.3 (1.2) 
NaF 21  11.3 (1.8) 0.9 (0.9)  1.6 (0.8) 1.7 (1.3)      
Acidic citrate and NaF 21  11.6 (1.9) 0.1 (0.9) -0.1 (1.0) 0.6 (1.2)      
EDTA 21       13.3 (3.4) 2.0 (1.0) 3.5 (1.4) 4.7 (1.7) 









































Figure 3.1 Increase of mean tHcy concentrations in whole blood of 30 laboratory coworkers 
processed 0, 2, 4, and 6 h after collection. Blood was collected in tubes containing 
EDTA and stored at 0°C (■) or at room temperature (□), and blood was collected in 
tubes with acidic citrate and stored at room temperature (●) or stored at 37°C (○); bars, 
SEM of tHcy concentrations. 
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Discussion 
Blood cells produce homocysteine, which can lead to falsely increased plasma 
homocysteine concentrations. Thus, in the ideal setting, blood cells should be 
separated from plasma immediately after collection. In EDTA- containing blood, 
we found that tHcy concentrations increased at room temperature, which has 
been demonstrated before10,14. Even storage at 4°C has been associated with 
a smaller but steady increase of the tHcy concentration10. However, we found 
that tHcy concentrations remained stable for 6 h when EDTA-containing blood 
was stored at 0°C, which confirms the findings of Kittner et al.15. 
In a study by Møller and Rasmussen16, heparin containing tubes with sodium 
fluoride added to a concentration of 2 or 4 g/l of blood prevented the increase 
of tHcy for only 2 h. In our pilot study and also in the study by Ubbink et al.10, 
comparable results of increasing tHcy concentrations were found by using 
2.5 g/l sodium fluoride.  
This investigation is the first concerning the stability of tHcy concentrations in 
whole blood containing acidic citrate. This tube contains citrate at a low pH of 
4.3 (pH±5.9 after blood collection) and was originally developed for the 
determination of fibrinolytic markers. During studies on fibrinolytic markers in 
relation to homocysteine, we found that tHcy might not increase in these 
samples at room temperature (data not shown). In our pilot study, we tested 
the combination of acidic citrate with sodium fluoride but found no difference 
between the tubes containing just acidic citrate and the tubes combining acidic 
citrate with sodium fluoride. Therefore, the stability of tHcy could be solely 
attributed to the acidic citrate fluid, making the addition of sodium fluoride 
unnecessary. 
We performed this study to find a collection medium that is suitable in 
epidemiological field conditions. We therefore also tested how tHcy 
concentrations behave when whole blood, taken in acidic citrate tubes, is 
stored at a temperature higher than room temperature. When blood was stored 
at 37°C, tHcy concentrations were increased after 4 h. We do not know the 
mechanism by which the acidic citrate keeps tHcy concentrations stable. It is 
possible that the enzymes involved in homocysteine metabolism are blocked at 
this low pH. This blockage, however, is temperature dependent because tHcy 
concentrations rise when blood is stored at 37°C. Baseline tHcy concentrations 
in the EDTA-containing tubes kept at room temperature and centrifuged at 
t=0 h were higher than the concentrations in EDTA tubes put on ice and 
centrifuged at 0 h. As mentioned earlier, there was a time interval between the 
venipuncture and the centrifugation of the blood at t=0 of, at most, 15 min. 
When cooling of the blood instantly stops the export of homocysteine, tHcy 
concentrations increase in blood that is kept at room temperature from the time 
between the blood samples being taken and the separation of plasma from 
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blood cells because of ongoing export, explaining the difference at t=0. We 
also found a difference between the mean baseline concentrations of tHcy 
measured in EDTA- treated blood that was stored at 0°C and tHcy 
concentrations in blood taken in acidic citrate. This difference can only partly be 
explained in the same way as above (i.e., a rise of tHcy concentrations in the 
time interval between blood sampling and separation). Other factors, such as a 
higher osmolarity of EDTA than acidic citrate, leading to higher plasma 
volumes, could be responsible for the difference. This, however, needs needs 
further investigation. This study was conducted to find an alternative collection 
medium for the determination of tHcy concentrations in plasma. When blood is 
collected outside a hospital or laboratory setting (e.g., in a large 
epidemiological study), it is not always possible to put blood tubes on crushed 
ice. Even within hospitals, it can easily be forgotten or found impractical to put 
the tubes on crushed ice before processing. Therefore, this method can be 
prone to inappropriate handling of blood for determination of tHcy 
concentrations. This study shows that acidic citrate is a good alternative when 
screening patients in an epidemiological field study because tHcy 
concentrations stay stable for 6 h. However, because of the differences found 
between the mean baseline tHcy concentrations in EDTA on ice and in acidic 
citrate at room temperature, new reference values need to be established 
before tHcy concentrations obtained in EDTA tubes and stored on crushed ice 
can be replaced by acidic citrate tubes for determination of tHcy concentrations 
in individual patients. 
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In epidemiological studies, blood handeling for measurement of homocysteine is cumbersome 
because at room temperature homocysteine production in whole blood continues after blood 
collection. Acidic citrate stabilizes homocysteineproduction in whole blood at room temperature. In 
a previous study baseline differences in homocysteine concentration were found between EDTA 
and acidic citrate anticoagulated blood. This study was performed to further explore this difference 
in homocysteine concentration. 
Blood from 208 volunteers was collected in tubes ontaining EDTA and acidic citrate as 
anticoagulant. The blood was processed within 30 minutes. Homocysteine determination in the 
plasma was done with 2 HPLC methods [HPLC(a) and (b)] and with an automated FPIA method. 
The mean differences in homocysteine between acidic citrate blood and EDTA blood with HPLC(a), 
HPLC(b) and FPIA were 1.8 µmol/l (95% CI 1.6 to 2.1 µmol/l), -2.8 µmol/l (95% CI –3.1 to 
-2.5 µmol/l) and 0.1 µmol/l (95% CI 0.0 to 0.3 µmol/l) resp. 
With all three measurement methods homocysteine concentrations in acidic citrate blood correlated 
well with homocysteine concentrations in EDTA blood. Regression analyses showed a slopes and 
intercept of 1.01 and 1.7 for HPLC(a), 0.75 and 0.7 for HPLC(b) and 0.95 and 0.7 for the FPIA. 
We conclude that acidic citrate can be used for measurement of homocysteine with all three 
measurement methods. However, when using these methods, new reference values need to be 
established, because there is a difference in individual concentrations in acidic citrate and EDTA 
blood. 
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Introduction 
In the past decade several studies have shown an association of 
hyperhomocysteinemia with arterial vascular disease1-3, venous thrombosis4, 
pregnancy complications5 and Alzheimers disease6,7. Blood collection for 
homocysteine measurement is usually done in tubes containing EDTA as 
anticoagulant. The tubes have to be put on melting ice immediately and have to 
be centrifugated within 1 or 2 hours. At room temperature there is an increase 
in homocysteine in whole blood8-12. This procedure with tubes being placed on 
ice and centrifugated within 1 or 2 hours is cumbersome in a clinical setting, but 
in particular in large epidemiological studies. Therefore several methods are 
proposed to stabilize homocysteine in whole blood. 
In a previous study we found that citrate with a low pH (pH=4.3, after blood 
collection ~5.9) stabilizes plasma homocysteine concentrations in whole blood 
for 6 hours when the blood is stored at room temperature12. However, we found 
a small difference in absolute homocysteine concentration measured in acidic 
citrate anticoagulated blood compared to EDTA.  
The purpose of the current study is to further explore the differences in 
homocysteine concentrations between EDTA and acidic citrate anticoagulated 
blood and to investigate whether the differences are the same for different 
methods for measurement of homocysteine. 
Methods 
Blood was collected from volunteers who were selected from a general practice 
in Beverwaard, Rotterdam, the Netherlands. Thousand people were randomly 
selected from the practice and addressed by mail to participate as controls in a 
case-control study. A total of 258 participated. We draw additional blood tubes 
to perform our comparison study. All volunteers gave their informed consent 
according to the revised Helsinki declaration. 
Blood was collected by venipuncture in 10 ml tubes containing EDTA 
(VacutainerR, Bencton&Dickinson, U.S.A.), and 5 ml tubes with acidic citrate 
(StabilyteR, Biopool, Sweden) as anticoagulant. Care was taken that the acidic 
citrate tubes were completely filled in order to obtain a blood:anticoagulant ratio 
of 9:1 in every sample. Blood collected in the EDTA tubes was stored at 0°C 
(melting ice) immediately after blood sampling until processing. Blood in the 
tubes with acidic citrate was kept at room temperature. All samples were 
processed within 30 minutes. They were centrifugated for 10 minutes at 2000 g 
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in a non-cooled centrifuge. The plasma was divided into aliquots and stored at 
–30°C until determination of the homocysteine.  
 
The homocysteine was measured with three different methods: 
1. HPLC(a): Automated high-performance liquid chromatography (HPLC) with 
reverse phase separation and fluorescent detection (Gilson 232-401 sample 
processor (Gilson Medical Electronics Inc., Middleton,WI), Spectra-Physics 
8800 solvent delivery system and Spectra-Physics LC 304 fluorometer (San 
Jose,CA)), according to the method described by Fiskerstrand et al.13 with 
some modifications14. The reagents used for the reduction are NaBH4 and 
DTE. For the derivatization procedure we used ethylmorpholine buffer and 
monobromobimane.  
2. HPLC(b): Automated high-performance liquid chromatography with 
reversedphase seperation and fluorescence detection according to Araki et 
al.15 and modified by Ubbink et al.16. With this method homocysteine is 
reduced with tri-N-butylphosphine and the derivatization is done with SBD-F 
in borate buffer. 
3. FPIA: A commercially available fluorescence polarization immunoassay 
(FPIA)(IMx Homocysteine, Abbott Diagnostics)17. This method, as the above 
mentioned HPLC methods, begins with the reduction of homocysteine using 
DTT. The homocysteine is enzymetically converted to SAH using adenosine 
and SAH hydrolase. Subsequent steps are adding mouse monoclonal 
antibodies and a fluoresceinated tracer before the homocysteine 
measurement. The assay is fully automated and can easily be applied in 
laboratories who do not have HPLC equipment but do have the means for 
an FPIA.  
 
Homocysteine concentrations measured in acidic citrate were corrected for the 
amount of fluid present in the tube prior to the blood collection by multiplying 
the measured concentration with 10/9. We did not correct for the fluid present 
in the EDTA tubes prior to collection (i.e., 0.117 ml), since the difference is 
negliable (±1%). All homocysteine measurements with HPLC(a) were corrected 
by subtracting 2.4 µmol/l from the measured concentration, according to the 
results as descibed by de Bree et al.11. 
Statistics 
The mean homocysteine concentrations in acidic citrate and EDTA were 
compared by paired-samples T-tests.  
We studied the association of homocysteine concentrations in acidic citate 
plasma and EDTA plasma with liniair regression for HPLC(a), HPLC(b) and 
FPIA.  
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Furthermore, to study the differences in individual values we plotted the mean 
difference of two individual measurements against the difference, according to 
the method described by Bland and Altman18. This method gives information 
about the spread of the differences between the individual values. We 
calculated the mean proportional bias (i.e., the mean difference in percentages) 
and the corresponding 95% confidence intervals (expressed as ‘limits of 
agreement’) after log-transformation of the homocysteine concentrations.  
Results 
Blood was obtained from 258 volunteers. From 50 volunteers there was an 
insufficient amount of plasma to perform all six analyses. Of 208 persons (79 
male, 129 female; age 23-88, median 65), all six measurement were available 
for the analyses. 
 
Homocysteine concentrations in EDTA and acidic citrate samples with the 3 
measurement methods are shown in boxplots in Figure 4.1. With HPLC(a) 
mean homocysteine measured in acidic citrate was 1.8 µmol/l (95% CI 1.6 to 
2.1 µmol/l) higher than in EDTA. Mean homocysteine in the acidic citrate was 
lower than in the EDTA samples (mean difference -2.8 µmol/l (95% CI 2.5 to 
3.1 µmol/l) when measured with HPLC(b). The mean difference in 
homocysteine concentration was the smallest with FPIA: 0.1 µmol/l (95% CI 0.0 
























































Figure 4.1 Boxplots of homocysteine measured in EDTA vs. acidic citrate anticoagulated blood. 
Measurement with 2 HPLC methods and FPIA. 
 
 
The regression analysis of the homocysteine concentrations measured with 
HPLC(a) shows a slope of 1.01 (95% CI 0.96 to 1.07) and an intercept of 1.7 
(95% CI 1.1 to 2.4). With HPLC(b) the slope was 0.75 (95% CI 0.72 to 0.78) 
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and the intercept at 0.7 (95% CI 0.2 to 1.2), meaning that homocysteine are 
approximately 25% lower measured in acidic citrate than in EDTA. With FPIA 
we calculated a slope of 0.95 (95% CI 0.92–0.98) with an intercept of 0.7 (95% 




















































































































Figure 4.2 Total homocysteine (tHcy) in µmol/l in acidic citrate versus EDTA samples for 
HPLC(a), HPLC(b) and FPIA. (- - -  = line of equality, ─── = regression line) 
 
 
The agreement of the individual concentrations is shown in the Bland-Altman 
plots. They show the spread of the differences between the individual 
measurements (Figure 4.3). It shows us that the acidic citrate values agree the 
most in the FPIA method. This is also shown in Table 4.1 in which the upper 
and lower levels of agreement are shown after log-transformation. The limits of 
agreement are the broadest with HPLC(b). This is a result of the fact that the 
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homocysteine concentrations in the acidic citrate tubes are approximately 75% 
of the concentrations in EDTA. With increasing concentrations the difference 
between individual concentrations gets higher but also the mean difference 
increases, so analysis of the limits of agreement results in a broad interval 
between the limits of agreement. 
 
 
Table 4.1 Difference between homocysteine concentrations in acidic citrate and EDTA. 
 Mean difference in µmol/l
(EDTA – acidic citrate) 




Lower limit of 
agreement 
Upper limit of 
agreement 
HPLC(a)  -1.8  -2.1 to -1.6  -16%  -40%  15% 
HPLC(b)  2.8  2.5 to 3.1  24%  -4%  62% 
FPIA  -0.1  -0.3 to 0.0  2%  -19%  16% 
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Figure 4.3 Bland-Altman plots of homocysteine measured in EDTA vs. acidic citrate anti-
coagulated blood. Measurement with 2 HPLC methods and FPIA. 
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Discussion 
Large epidemiological studies require blood collection techniques that are 
easily applicable in a field setting. Difficult blood collection techniques are 
sensitive to blood handling mistakes, which causes loss of information. For 
homocysteine measurement, storage of whole blood collected in EDTA prior to 
centrifugation should be done at 0°C to prevent elevation of homocysteine due 
to the homocysteineproduction by the blood cells, mainly the erythrocytes. 
Several alternative collection media have been proposed. Fluoride stabilized 
homocysteine for 2 hours at room temperature in several studies8,12,19, but this 
could not be reproduced in other studies20-23. Hughes et al. also showed that 
sodium fluoride causes additional dilution defects, leading to lower plasma 
homocysteine concentrations at baseline and advises not to use NaF as 
anticoagulant for homocysteine measurement20. Probst et al. developed a 
collection device in which whole blood is lysed. Homocysteine remained stable 
in this lysate for 48 hours at room temperature24. Hill investigated 
3-deazaadenosine (3DA) and found that EDTA blood with added 3DA 
stabilized homocysteine for 72 hours when stored at 2-8°C25. However, when 
the blood was stored at room temperature, homocysteine concentrations 
increased.  
We previously reported that acidic citrate stabilizes homocysteine in whole 
blood at room temperature for 6 hours12. Our finding was confirmed by Salazar 
et al.26. They found that homocysteine stayed stable up to 6 hours when the 
measurement was done by HPLC. They used a HPLC method27 that differed 
form ours. However, when they measured with FPIA, they found an increase in 
homocysteine in both acidic citrate and EDTA stored at 0°C26.  
 
The aim of the current study was to compare homocysteine measurement in 
acidic citrate plasma with homocysteine concentrations in EDTA plasma. We 
found that homocysteine measured in blood with acidic citrate as anticoagulant 
correlates well with homocysteine measured in blood with EDTA as 
anticoagulant, regardless of the method of measurement used. This is derived 
from the narrow 95% confidence intervals in the regression analyses. We also 
found that the absolute individual homocysteine concentrations in both media 
may differ. The level of agreement was the best with the FPIA method. 
We found differences between the mean homocysteine concentrations in acidic 
citrate compared with EDTA. This difference is not the same for each 
measurement method, thus depends on the method used. With HPLC(a) the 
difference is constant, meaning that the homocysteine measured in acidic 
citrate is approximately 1.7 µmol/l higher than in the EDTA samples. With 
HPLC(b) the difference is dependant of the level of the homocysteine, the 
absolute difference rises with increasing concentrations of homocysteine. On 
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average the homocysteine in the acidic citrate samples is 25% lower than in 
the EDTA samples. The difference in mean homocysteine was the smallest 
with the FPIA (0.1 µmol/l), with a regression line close to the line of equality.  
The difference we measured with HPLC(a) is comparable to the difference we 
found previously in a stability study in which homocysteine was 1.3 µmol/l 
higher in acidic citrate samples12. The same HPLC method was used in this 
study. With HPLC(b) we measured much lower homocysteine in the acidic 
citate samples. Salazar et al. found a smaller difference of 5% between 
homocysteine in EDTA and acidic citrate samples measured with HPLC, with 
homocysteine being lower in acidic citrate samples than in the EDTA 
samples26. We have hypothesized about the mechanisms causing 
homocysteine being higher in acidic citrate than in EDTA samples when 
measured with HPLC(a), and being lower with HPLC(b). We thought it could be 
a result of the acidic environement interacting with the measurement method. 
Therefore we added acid to EDTA plasma and did 10 additional measurements 
with HPLC(a), but the homocysteine concentrations in the regular EDTA 
plasma and the acidic EDTA plasma were comparable (data not shown). It may 
be that the reagents used in the measurement interact with homocysteine from 
acidic citrated plasma and influence the measurements. Since both HPLC 
methods use different reagents this could lead to the differences we found. 
The difference found between homocysteine in EDTA versus acidic citrate 
samples with the FPIA was small. In the same study as mentioned above, 
Salazar also used the same FPIA method as in our study and also found that 
homocysteine in acidic citrate samples did not differ significantly from the 
homocysteine concentrations in EDTA samples26. Palmer-Toy et al. compared 
homocysteine in EDTA and citrate (i.e., non-acidic citrate) anticoagulated blood 
measured with FPIA28. They also found no difference between homocysteine in 
the collection media when they corrected the homocysteine values from the 
citrate samples with a correction factor. This correction factor corrected for 
hematocrit, based on gender and the added amounts of anticoagulant present 
in the collection tube before blood sampling. We used the same correction 
factor to transform our homocysteine values from the acidic citrate samples 
measured with FPIA and did the regression analysis for the FPIA method 
again, but this did not influence the results. 
 
Based on the results of this study, we conclude that tubes with acidic citrate 
can be used in epidemiological studies since homocysteine concentrations 
correlate highly with those measured in EDTA plasma. Reference values need 
to be established when using acidic citrate tubes since individual values differ 
from those measured in EDTA samples and the difference is dependent on the 
measurement method being used. Individual values differ between EDTA and 
acidic citrate samples, therefore the two media cannot be compared directly. 
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High circulating levels of homocysteine are a risk factor for arterial and venous thrombosis. This 
association has been established in numerous case-control studies. In some of these studies 
patients were treated with anticoagulants at the time of venapuncture. It is not clear whether 
homocysteine concentrations are influenced by anticoagulants. If there is an effect of 
anticoagulation on homocysteine levels this might under- or over-score the possible association of 
homocysteine levels and vascular disease.  
 
Methods 
In this study we used two different groups to investigate the association of coumarin derivatives on 
homocysteine concentrations. Homocysteine levels were measured in patients (N=40) who were 
on the waiting list for orthopedic surgery and were expected to receive prophylactic anticoagulant 
therapy after the operation. We measured homocysteine concentrations before the operation, and 
during and after coumarin therapy. In a second study group, we measured homocysteine 
concentrations in 12 healthy volunteers who were treated with oral anticoagulants. 
 
Results 
Mean homocysteine concentrations increased 6% (95% CI 2% to 10%) during the treatment with 
coumarin derivatives. This corresponds with 1 µmol/l increase in homocysteine concentration. After 
the anticoagulant treatment period the concentrations decreased again. We calculated that this 
slight increase does not influence the interpretation of epidemiological studies. No influence on 
homocysteine concentrations was observed: decrease 3.6% (~0.6 µmol/l) (95% CI –17.5% to 
8.5%) after 13 weeks of treatment with anticoagulants in healthy volunteers. 
 
Conclusion 
We conclude that there is no important effect of anticoagulation on homocysteine concentrations. 
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Introduction 
Homocysteine is an aminoacid, formed after demethylation of methionine. It is 
either transsulphurated to cysteine or remethylated to methionine. Increased 
homocysteine concentrations are associated with arterial and venous 
thrombosis1-4. The association between homocysteine levels and arterial and 
venous thrombosis has been established in prospective studies, but mainly in 
retrospective case-control studies. In several of these studies on venous 
thrombosis, the patients were on treatment with anticoagulants at the time of 
venapuncture. In studies on arterial vascular disease many patients are also 
using coumarin derivatives, even in a prospective design. If anticoagulants 
influence the homocysteine concentrations, relative risk estimates will have 
been overestimated or underestimated. An influence of anticoagulants on 
homocysteine values could interfere with the outcome of these studies, 
especially since the odds ratios in the presented studies are usually small. To 
our knowledge there is no theoretical reason to believe that anticoagulants do 
influence homocysteine values. The aim of our study was to assess whether 
coumarin derivatives affect plasma homocysteine concentration in vivo. For this 
we measured plasma homocysteine concentrations before during and after 
anticoagulant treatment in two study groups. The first group underwent surgery 
and was treated with anticoagulants as prophylaxis; the second group were 
healthy volunteers who participated in a pharmacologic study.  
Methods 
Patient selection 
We selected two study groups to assess the influence of coumarins on 
homocysteine. The first group were patients selected from the department of 
Orthopedics of the Leyenburg Hospital. Patients were all waiting for a hip- or 
knee-replacement operation and were asked to participate in this study. They 
were scheduled to take coumarin derivatives (acenocoumarol or phen-
procoumon) until 3 months after the operation. Patients were excluded if they 
were using drugs that influence homocysteine- or folate concentrations (vitamin 
B, folic acid, methotrexate, phenytoin). 64 Consecutive patients were enrolled. 
Of these 64 patients, 24 patients were excluded for the following reasons: 
missing blood samples due to not showing up at follow-up visits, continued use 
of oral anticoagulant therapy, use of vitamin B after the start of the study, 
previously unmentioned use of oral anticoagulant therapy before the start of the 
study. Homocysteine concentrations of the remaining 40 patients (9 male, 31 
female; age 47-88 years, median 71) were used for the analysis.  
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A second study was carried out in 12 healthy volunteers (6 men, 6 women, age 
25-31 years) who took part in a study to evaluate the effect of low-dose vitamin 
K on INR levels. All volunteers were treated with coumarins (acenocoumarol) 
and adjusted to an INR of 2.0. The subjects were first adjusted to a stable INR 
(week 1-4) and subsequently supplemented with increasing doses of synthetic 
vitamin K1 (in tablet form) over a 7-week period (weeks 5-11). Each K1 dose 
was taken daily for a one-week period (Monday to Sunday), and in successive 
weeks the dosage was increased in increments of 50 µg K1 over the range 
50 µg to 300 µg, increasing to 500 µg K1 for the final week. After the vitamin K 
supplementation period was a two week wash-out period (week 12 and 13). 
Blood sampling and homocysteine measurements 
Non-fasting blood (acidic citrate, Biopool, Stabilyte®) was taken three times 
from each patient in the first group of patients: before the operation, two 
months after the operation (on coumarin derivatives) and two months after 
cessation of the coumarin therapy. Blood was centrifuged within 30 minutes 
after collection at 2000g for 10 minutes. Plasma was separated and stored at 
-30ºC until serial determinations. In a subset of the patients blood was 
collected in EDTA (Vacutainer®, Beckton&Dickinson) for determination of folate 
and vitamin B 12 concentrations, according to standard techniques.  
In the second group we determined homocysteine concentrations in 
standardized non-fasting morning samples (EDTA plasma). Blood was 
centrifuged within 30 minutes and stored at –20ºC. Samples were taken at the 
start of the study (before coumarin therapy was started), after week 4 (before 
the start of the low dose vitamin K), after week 10 (after combined vitamin K 
and coumarin treatment), and after week 13 (after the wash-out period of the 
vitamin K). The inclusion of this study group gives us the possibility to study 
both the effect of the drug medications as well as the anticoagulant effect on 
homocysteine levels. Details of the second study group have been published 
by Schurgers et al.5.  
Homocysteine concentrations of both study groups were determined using an 
automated high-performance liquid chromatography with reverse phase 
separation and fluorescence detection (Gilson 232-401 sample processor 
(Gilson Medical Electronics Inc., Middleton,WI), Spectra-Physics 8800 solvent 
delivery system and Spectra-Physics LC 304 fluorometer (San Jose,CA)), 
according to the method described by Fiskerstrand et al.6 with some 
modifications7.  
Folate and vitamin B12 concentrations are determinants of the homocysteine 
concentration8. We measured folate and B12 with IMx Automated 
Immunoassay Analyzer (Abbott®) in a subset of patients of the surgery group. 
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Statistics 
Paired-samples T-tests were used to compare geometric means of 
homocysteine, vitamin B12 and folate concentrations. Results are presented in 
percentages with 95% confidence intervals. 
 
The study protocol was approved by the Leyenburg Ethics Committee for the 
surgery group. For the second study group, approval was granted by the 
Medical Ethics Committee of the University of Maastricht. All persons gave 
their informed consent according to the revised Helsinki declaration (1975). 
Results 
Figure 5.1 shows the individual values of the mean homocysteine 
concentration before during and after coumarin therapy in 40 patients. 
Geometric mean homocysteine concentration during coumarin therapy was 6% 
higher than before the start of coumarin therapy (95% confidence interval (CI) 
2% to 10%; p=0.01). Absolute values increased from 16.4 µmol/l to 17.4 µmol/l. 
After cessation of the coumarins homocysteine decreased 4% (95% CI –1% to 
10%; p=0.1) (absolute values 17.4 µmol/l to 16.7 µmol/l). The geometric mean 
difference between the concentrations before and after coumarin therapy was 












































Figure 5.1 Mean homocysteine concentrations (Hcy) ± 2SD and individual homocysteine 
concentrations before the start of coumarin therapy, during coumarin therapy and after 
coumarin therapy in a group of surgery patients. See text for values. 
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Although the possible effect of anticoagulans on homocysteine values is very 
low, we analyzed if the 1 µmol/l increase in homocysteine concentration found 
in the surgery group was indeed due to treatment with anticoagulant drugs, we 
measured homocysteine concentrations in 12 volunteers who were treated with 
oral anticoagulants for 13 weeks. We found that geometric mean homocysteine 
concentrations decreased with 1.6% (95% CI –3.9% to 7.0%; p=0.5) after 4 
weeks of treatment with oral anticoagulants, subsequently increased after 
vitamin K (2.9% (95% CI –5.2% to –0.4%); p=0.02), and decreased again after 
the wash-out of vitamin K (4.7% (95% CI –2% to 11%; p>0.05) The absolute 
values were 10.7, 10.1, 10.8, and 10.0 µmol/l, respectively. The individual 
concentrations and the mean INR levels in the study are shown in Figure 5.2. 
We conclude that there is no influence of anticoagulants on homocysteine 











































Figure 5.2 Homocysteine concentrations in 12 healthy volunteers treated with oral anticogulants 
and low-dose vitamin K. 
 1 = week 0.  Before coumarins, mean INR=1.0 
 2 = week 4.  After 4 weeks of coumarin therapy, mean INR=2.1 
 3 = week 10.  After 11 weeks of coumarin therapy in combination with increasing 
doses of vitamin K, mean INR=1.4 
 4 = week 13.  After the wash-out period of vitamin K, mean INR=1.9 
 
 
We determined plasma vitamin B12 and folate concentrations in a subset of 27 
surgery patients. No influence on vitamin B12 was observed (data not shown). 
However, folate level declined slightly (mean value from 6.7 nmol/l to 
5.7 nmol/l), but not significantly (13%, 95% CI -3 to 27%; p=0.1). This was, 
however not associated with anticoagulant drugs since we saw no recovery 
after anticoagulant withdrawal but even a further decline from 5.7 nmol/l to 
5.2 nmol/l (10 %, 95% CI –3% to 24%; p=0.1). 
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Figure 5.3 Percentile increase of homocysteine levels while on coumarin therapy in relation to the 
time interval passed since the operation(A) and percentile decrease of homocysteine 
levels after cessation of coumarin therapy(B) 
 
Discussion 
In this study we found a slight increase in homocysteine concentration in 
patients on prophylactic anticoagulant therapy for surgery. However, this effect 
was very small with a difference of 6% only, which corresponds to 1 µmol/l. In a 
group of healthy volunteers we found no influence of anticoagulants on 
homocysteine values at all. 
The question is whether the slight increase in the surgery group was found due 
to coumarin use, or as an effect of the operation. We hypothesized that if there 
is an effect of the operation, it will diminish in the course of time. We compared 
the percentile increase in homocysteine concentration between the first (before 
coumarins) and the second (on coumarins) blood sample with the time elapsed 
after the operation. As shown in Figure 5.3A there was no relation between 
times elapsed after the operation and the percentile increase in homocysteine 
concentration (r=-0.1). In addition, we also determined the decrease in 
homocysteine concentration after the cessation of coumarins in relation to the 
time elapsed. Also, if the rise would be an effect of the coumarin use, the 
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percentile decrease after cessation of the coumarins would be greater when 
more time has passed. However, we found no relation between the time 
elapsed after the cessation of coumarins and the percentile decrease (Figure 
5.3B) (r=0.07). A control group having similar surgery without anticoagulants is 
not possible for ethical reasons. A control group having a different form of 
thrombosis prophylaxis - like heparins – could have given information on the 
possible effect of different forms of anticoagulant treatment on homocysteine 
values versus the surgery procedure per se, but was not available.  
 
The effect we observed in the surgery group was much smaller than the effect 
of coumarin use on homocysteine levels as found by Murua et al.9. They found 
a median difference of 9 µmol/l between a group of chronically anticoagulated 
patients with mitral valve replacement, atrial fibrillation and dilated 
cardiomyopathy in comparison to a group of patients with atherosclerosis who 
were not treated with coumarins. The authors concluded that this increase in 
homocysteine concentration was due to the lower folate levels in the patients 
on coumarins. The difference between the observation of Murua et al. and this 
study might be explained by the duration of coumarin treatment. Our study was 
aimed at analysing anticoagulants per se interfering with homocysteine values. 
Following patients for a longer period of time could coincide with a change in 
other variables such as folate levels observed by Murua. 
The slight increase in homocysteine levels we found in the surgery group can 
be influenced by several factors. First, all our patients had a knee or hip 
replacement the day after the first blood sample was drawn. The use of nitrous 
oxide during operations can cause increments in homocysteine by cobalamin 
dependent blockage of methionine synthase10-12, an enzyme necessary for the 
re-methylation of homocysteine. It has been shown to affect homocysteine 
concentrations up to one week postoperatively12, but it is not known whether 
this effect lasts longer. When nitrous oxide is not used as an anesthetic, 
homocysteine is shown to remain stable11 or even decrease13. Long-term 
effects of operations on homocysteine concentrations have not been reported. 
We reasoned that the effect would diminish in the course of time. The data 
shown in Figure 5.3A do not support the hypothesis that homocysteine 
concentrations increase due to a late effect of the operation: there is no relation 
between the time elapsed since the surgery and the increase in homocysteine, 
making an effect of aneshtesia on homocysteine concentrations unlikely.  
Despite the fact that the influence on homocysteine concentration was very low 
in the surgery group, people who underwent this kind of major surgery, may 
have alterations in dietary habits, e.g. reduced folic acid and vitamin B12 
intake. We did not observe an influence on vitamin B12 levels but a slight 
decline in plasma folate levels. The folate concentrations decreased even 
further after withdrawal of anticoagulants. Possibly, folate levels are an inpact 
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determinant of homocysteine values after surgery. This mechanism would fit to 
the analysis of Murua et al.9. 
Since we observed a minor effect in the surgery group, we subsequently 
studied the effect of coumarin treatment on homocysteine levels in a group of 
healthy volunteers. This way we were able to separate the effect of coumarins 
and surgery. In this group we found no effect in homocysteine concentrations 
during anticoagulant treatment. Since we found no effect of anticoagulant use 
in the healthy controls it is most plausible that the small effect in the surgery 
group was caused by clinical circumstances and not to the anticoagulant per 
se. 
Many interactions of drugs and homocysteine concentrations have been 
described. Examples of these drugs are: B-vitamins, anti-folates like 
methotrexate, anti-epileptic drugs like phenytoin, the nitrous oxide and 
estrogens8. Most of these interactions are a result of direct influence of the 
drug on the metabolic pathways involved in homocysteine metabolism. As far 
as we know, the metabolic pathways of homocysteine and coumarins are not 
interchanged, and our results support the conclusion that there is no 
interaction.  
Although an influence of coumarins on homocysteine levels is unlikely, we 
calculated wether a slight change in homocysteine levels as observed in the 
surgery group would affect the risk estimates in case-control studies in which 
only the cases used anticoagulant therapy. When homocysteine levels 
increase during anticoagulant therapy, more cases will have hyperhomo-
cysteinemia and fewer cases will have a normal homocysteine concentration, 
resulting in a falsely elevated odds ratio. We calculated the impact of the 6% 
increase we found in our surgery group and we obtained correction factors of 
0.89 for the 75th, 0.88 for the 90th and 0.88 for the 95th percentile (using 
reference values of a case control study we performed earlier2). Thus, if an 
effect of coumarins on homocysteine concentration would indeed exist - at a 
level 1 µmol/l increase - this would have had only a very small effect on the 
odds ratios from comparing studies in which coumarins were used in patients 
and not controls.  
Usually, the increase in homocysteine concentration in patients at risk for 
vascular disease is expressed as odds ratio per 5 µmol/l. For venous 
thrombosis this odds ratio is approximately 1.61, for stroke and ischemic heart 
disease 1.4 and 1.2 respectively3. A change of 1 µmol/l in homocysteine 
concentration, as we found in the surgery group, corresponds with a risk ratio 
of approximately 1.01. Therefore, when homocysteine concentrations are 
measured in a screening program for cardiovascular risk factors in individual 
patients, the use of anticoagulant therapy during this screening has no 
significant impact on the risk estimate. Moreover, because results from 
adequate intervention trials in atherosclerosis are conflicting14-16, and the 
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results of intervention trials in venous thrombosis are still limited17 the benefit of 
determination of individual homocysteine concentrations remains unclear. 
In conclusion, we found a slight but not relevant increase in homocysteine 
values in patients who were on anticoagulant therapy because of orthopedic 
surgery, and no influence in healthy volunteers taking anticoagulants for 
scientific reasons. We conclude that anticoagulants per se do not influence 
homocysteine values at a level to consider relevant in epidemiological studies 
nor in individual patient care.  
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Introduction 
Several case control studies and a recent prospective study showed that in 
patients with (idiopathic) venous thrombosis mild hyperhomocysteinemia (HH) 
can be observed 2-3 times more frequently than in controls1-3. The 
pathogenetic explanation for this clinical observation is not known. In principal 
a thrombotic tendency can originate in the blood, in the vessel wall or at the 
level of thrombocytes. The question that we wanted to answer was whether the 
thrombotic tendency that might accompany HH is caused by a higher capacity 
of these persons to generate thrombin. The plasmatic component of a 
thrombotic tendency might be reflected in the capacity of the platelet poor 
plasma to generate thrombin. This capacity can be assessed by measuring the 
endogenous thrombin potential (ETP), i.e. the surface under the thrombin 
generation curve4-6. It has been shown that the ETP is significantly increased in 
such plasma based thrombotic tendencies as deficiencies in AT and mutated 
Factor V Leiden6,7. The influence of exogenous activated protein C (APC)8,9 
and exogenous thrombomodulin (TM)10,11 on the inhibition of the ETP was 
recently shown and was used to screen for a deficient protein C pathway. In 
order to see whether a plasmatic component can explain the thrombotic 
tendency in HH, we tested the possible relationship between the concentration 
of homocysteine (tHcy) and thrombin generation in a group of healthy controls, 
without any venous thrombotic events in the past. 
Methods 
Blood samples of 30 persons with elevated levels of tHcy (>18 µmol/l; mean: 
22.7 mmol/l) were selected. Samples of 30 persons matched for age and sex 
with normal tHcy levels (mean: 14.2 µmol/l) were used as controls (for details 
on study group selection see ref. 12). Homocysteine values of >18 µmol/l are 
clearly associated with increased risk for venous thrombosis13,14. We 
deliberately did not include patients with venous thrombosis in the past, so as 
to exclude the possibility of plasma changes caused by the thrombotic process 
itself. We determined the ETP under standard conditions (extrinsically and 
intrinsically) and in the presence of exogenous APC or TM. The assay method 
for determining the ETP is based on the continuous monitoring of thrombin 
formation using a slow reacting thrombin substrate essentially as described 
earlier4 which method has been adapted for high throughput screening on a 
Cobas centrifugal analyzer6. The anticoagulant response towards TM was 
expressed as the thrombomodulin ratio (TMR); TMR: (ETP+TM/ETP-TM)pool/ 
(ETP+TM /ETP-TM)sample. The anticoagulant response towards APC was 
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expressed as the APC sensitivity ratio (APC-sr): (a2M–IIa+APC/a2M–IIa-
APC)sample / (a2M–IIa+APC/a2M–IIa-APC)pool. 
Results 
The data on the subjects under study are given in Table 6.1. There was a 
narrow association between the intrinsic and extrinsic ETP. The Pearson 
correlation is 0.876 (p=0.001) (data not shown). However, for both intrinsic ETP 
and extrinsic ETP we found no correlation with tHcy. Comparing the two 
different groups no difference was present between those with normal tHcy 
levels and those with elevated tHcy levels. The intrinsic ETP in those with 
elevated tHcy was 412 (99% of reference plasma) similar to those with normal 
tHcy. The extrinsic ETP was 100% of reference plasma in those with eleveated 
tHcy and 106% of reference plasma in those with normal tHcy. There was 
clearly no association between tHcy and TMR (coefficient is 0.04; p=0.74) and 
no difference between the group with high tHcy and those with normal tHcy 
was observed. Also no difference in APC-sr ratio could be observed between 
those with high and normal tHcy levels. 
 
 
Table 6.1 Homocysteine and ETP values of persons under study. 
 normal tHcy high tHcy p-value 
tHcy mean (µmol/l) 14.2 22.7  
tHcy range 8.4 – 16.5 18.0 – 49.8  
Mean age (range) 55.2 (23 - 82) 55.1 (23 - 80)  
Male (N) 15 15  
Female (N) 15 15  
ETP intrinsic 412 +/- 72 nM.Min 412 +/- 66 nM.Min  0.6 
ETP extrinsic 419 +/- 65 nM.Min 395 +/- 56 nM.Min  0.15 
APC-sr 1.37 +/- 0.33 1.41 +/- 0.51  0.75 
TMR 0.83 +/- 0.15 0.86 +/- 0.18  0.37 
 
Discussion 
Since no association of the ETP and homocysteine levels was observed and 
no influence of homocysteine on the ETP in the presence of APC or TM, our 
data do not support the idea that HH acts via the plasmatic coagulation system. 
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Others suggested a role for factor V or activated protein C. In addition an 
enhanced turnover or diminished formation of thrombomodulin has been 
suggested though not supported by all studies (reviewed in 1 and 15). It should 
be realized however that most of the observations were made in in vitro 
systems and that in the in vitro experiments very high levels of (free) 
homocysteine – up to 10 mmol/l – were used. These values differ far from the 
in vivo situation and it is questionable in our opinion whether these in vitro 
experiments represent the clinical situation. Not finding an association between 
mild HH and the ETP renders a direct influence of HH on plasmatic thrombin 
generation improbable. Therefore other factors might be relevant such as the 
fibrinolytic pathway, enhanced tissue factor activity, enhanced platelet 
aggregation, increased platelet adhesion on endothelial cells, abnormal 
nitrogen oxides, abnormal endothelium-derived relaxing factor and inhibition of 
von Willebrand factor production1,15. Most of the studies supporting these 
hypotheses are however again limited by the high levels of homocysteine used 
in the in vitro experiments. It has also been shown that homocysteine might 
induce altered gene expression in endothelial cells, genes that might possibly 
be related to the process of thrombosis16,17. Until now –to our knowledge– there 
is however no clear parameter observed in man that might be a clue for the 
pathogenetic process involved in the association of mild HH and venous 
thrombosis. We feel such a parameter is urgently needed to proof that the 
epidemiological association between HH and venous thrombosis can more 
likely be interpreteted as a causative one. Furthermore such a parameter would 
be very helpful in treatment strategies for HH. Vitamins (folic acid) can easily 
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High plasma levels of homocysteine are a risk factor for venous thrombosis. Although thrombosis 
has a high incidence in elderly people, little is known about the risk of venous thrombosis related to 
hyperhomocysteinemia in the elderly .  
We performed a case-control study with 426 patients with a first, idiopathic and objectively 
diagnosed deep-vein thrombosis or pulmonary embolism and 294 control subjects from the general 
population. All subjects were >65 years of age. 
Mean homocysteine levels were higher in the cases (14.4 (95% CI 13.9 to 14.9) µmol/l) than in the 
controls (13.2 (95% CI 12.7 to 13.7) µmol/l). There was a linear relationship between quartiles of 
homocysteine concentration and thrombosis risk, with an odds ratio for the highest versus the 
lowest quartile of 1.7 (95% CI 1.1 to 2.7). 
We conclude that mild hyperhomocysteinemia is a risk factor for venous thrombosis in the elderly. 
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Introduction 
Venous thrombosis is a common disease, especially in the elderly. The 
incidence rises from approximately 25 / 100,000 / year at the age of 25 to 500 / 
100,000 / year over the age of 801. Immobility, malignancy and major surgery 
are well known environmental risk factors for venous thrombosis. These may in 
part explain why elderly patients are more at risk for developing venous 
thrombosis since the prevalence of these risk factors is higher at higher age, 
but it cannot explain the steep rise in incidence that is seen in the elderly.  
High levels of homocysteine are an established risk factor for venous 
thrombosis. The association has been established in numerous case-control 
studies and three prospective studies2. Most of these studies did not focus on 
elderly patients. Since plasma homocysteine levels increase exponentially with 
age3, homocysteine might play an important role in the development of venous 
thrombosis in this age group. Two previous studies have reported on the risk of 
hyperhomocysteinemia and the development of venous thrombosis and the 
relation with age. Den Heijer et al. found a sharp increase in the risk of 
thrombosis with age associated with hyperhomocysteinemia for both men and 
women4. The results of this study could not be confirmed by Tsai et al. who 
found no association between hyperhomocysteinemia and an increased risk of 
thrombosis at high age5. More studies on this subject are lacking. We therefore 
performed a case-control study among elderly patients to evaluate whether 
elevated homocysteine levels are a risk factor for venous thrombosis in this 
age group. 
Patients and methods 
Cases 
Cases were selected from the screening of the VITRO (vitamin and 
thrombosis) study. The design of the study was described previously6. In short, 
the VITRO study is a randomized, placebo-controlled, double-blind trial with 
multivitamin B as secondary prevention of venous thrombosis in patients with 
hyperhomocysteinemia. Patients for the trial were selected from seven 
anticoagulation clinics in the Netherlands from February 1995 to June 2000. 
Anticoagulation clinics monitor the treatment of virtually all patients on 
coumarins in a well described geographic area. All patients who were 
registered for treatment for a first deep-vein thrombosis or pulmonary embolism 
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were eligible for screening and asked to donate an extra blood tube for 
homocysteine measurement.  
In the current analysis we included patients from the anticoagulation clinics of 
The Hague and Rotterdam who were aged 65 years or older at the time of a 
first event of idiopathic venous thrombosis, which was diagnosed by objective 
methods (proximal deep-vein thrombosis by compression-ultrasonography or 
phlebography, pulmonary embolism by high-probability VQ-scanning, 
pulmonary angiography or spiral CT scanning). We considered as idiopathic 
events that were not preceeded by immobilisation (bed-rest, paresis, cask), 
major trauma or major surgery, vasculitis or intravenous catheters, or 
malignancy). Information on diagnostic methods and these risk factors were 
obtained from the treating physician.  
Control subjects 
Control subjects were selected from two general practices in The Hague and 
Rotterdam. In the Hague all persons of 65 years and older registered at this 
practice were asked by mail to participate. In the Rotterdam practice we 
randomly invited 500 persons of 65 years and older from all patients registered 
at the practice. They were eligible for participation in the absence of a previous 
venous thrombosis and malignancy. People with a malignancy were excluded 
from the analysis. 
Blood handling 
Blood was drawn before 10 a.m. in acidic citrate tubes (Biopool StabilyteTM). In 
a previous study we showed that acidic citrate stabilizes whole blood for 
measurement of homocysteine at 21°C7,8. Blood was stored at room 
temperature and was processed within 5 hours after collection. It was 
centrifuged for 10’ at 2000g in a non-cooled centrifuge. The plasma was 
separated and stored at -30°C until determination of the homocysteine 
concentration.  
Homocysteine was determined by automated high-performance liquid 
chromatography (HPLC) with reverse phase separation and fluorescent 
detection (Gilson 232-401 sample processor (Gilson Medical Electronics Inc., 
Middleton,WI), Spectra-Physics 8800 solvent delivery system and Spectra-
Physics LC 304 fluorometer (San Jose,CA)), according to the method 
described by Fiskerstrand et al.9 with some modifications10,11. Homocysteine 
concentrations were multiplied by 10/9 as correction for the fluid present in the 
blood tube prior to collection.  
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Data analysis  
We calculated age and sex specific quartiles of homocysteine. The odds ratios 
for the second to the fourth quartile (with the first quartile as a reference 
category) was calculated with a logistic regression model. 
Results 
At the anticoagulation clinics of The Hague and Rotterdam we screened 2821 
patients for the VITRO study. Of these, 1195 were above 65 years. We 
obtained information about circumstances and diagnostic methods of the 
venous thrombosis of 1097 patients. Of these, 110 patients had a recurrence, 
and 572 patients had a first, idiopathic venous thrombosis of which 146 were 
not objectively diagnosed according to our entry criteria. This left 426 patients 
who met the participation criteria for the current study.  
From 1045 persons invited by mail to participate as control subject, 294 
consented to participate. Baseline characteristics of the patients and controls 
are shown in Table 7.1. There were more men in the patient group than in the 
control group (46% vs. 41%) and the mean age was higher in the patients 
group (74.5 vs 73.2 years).  
 
 
Table 7.1 Baseline characteristics of the patients and controls. 
 patients controls 
number 426 294 
men / women 196 / 230 120 / 174 
median age (range) in years 74 (65-93) 72 (65-96) 
mean homocysteine (range) in µmol/l 13.2 (12.7-13.7) 14.4 (13.9 – 14.9) 
   
thrombosis    
     deep-vein thrombisis 255  
     pulmonary embolism 135  




The distribution of the homocysteine concentrations of patients and control 
subjects is shown in Figure 7.1. Homocysteine was higher in men (1.5 (95% CI 
0.7 to 2.4) µmol/l) and increase with age both in men (3.0 (95% CI 0.8 to 5.2) 
per decade) and women (2.2 (95% CI 1.3 to 3.2) per decade). Therefore, we 
calculated the odds ratios for thrombosis for age- and sex- specific quartiles 
with the lowest quartile as the reference quartile (Figure 7.2). We found a linear 
dose-response relationship with an odds ratio for the highest versus the lowest 
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quartile of 1.7 (95% CI 1.1 to 2.7). There was no apparent difference in risk in 
the different age and sex groups. Stratification for type of thrombotic event did 
not show clear differences in risk for deep-vein thrombosis (odds ratio top 
versus bottom 1.9 (1.2 to 3.0)), pulmonary embolism (1.5 (0.8 to 2.7) or both 































































Figure 7.2 Thrombosis risk for age- and sex specific quartiles of homocysteine concentrations. 
Discussion 
We found that the homocysteine concentration in plasma is a risk factor for 
venous thrombosis in elderly individuals as it is among younger people. 
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Furthermore, we found a graded increase in the risk with increasing 
homocysteine concentrations.  
The risk estimate that we report in this study lies between that of our earlier 
study4 and the study of Tsai and colleagues5. In a case control study with 269 
patients with a deep-vein thrombosis and 269 age- and sex- matched controls 
we reported an increase in relative risk for hyperhomocysteinemia from 0.7 
(95% CI 0.1 to 4.0) under the age of 30, up to 5.5 (95% CI 1.2 to 5.2) over the 
age of 50. This graded increase in risk was seen in both men and women.  
However, Tsai and colleagues looked at homocysteine as risk factor for venous 
thromboembolism in the LITE study, a nested case-control study5. They found 
an overall odds ratio of 1.55 (95% CI 0.93 to 2.58) for the highest versus the 
lowest quintile. They report an attenuation of the association with increasing 
age, and absence of any excess risk above 65 years.  
In the current study the risk estimate, as an odds ratio, is very similar to those 
reported in studies in younger patient groups. Even though the odds ratios we 
calculated are similar to those in studies of younger subjects, this may imply 
that the absolute effect of hyperhomocysteinemia is greater among the elderly, 
because the incidence of thrombosis is much higher1. 
In conclusion, homocysteine is a risk factor for venous thrombosis in patients 
above 65 years old. 
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The VITRO (VItamins and ThROmbosis) study investigated the effect of homocysteine lowering by 
daily supplementation of B-vitamins on the risk reduction of deep-vein thrombosis and pulmonary 
embolism. Patients between 20 to 80 years old with a first objectively confirmed proximal deep-vein 
thrombosis or pulmonary embolism in the absence of major risk factors and a homocysteine 
concentration above the 75th percentile of a reference group were asked to participate 
(hyperhomocysteinemic group). A similar study was conducted in a random sample of patients with 
a homocysteine below the 75th percentile of the reference group (normohomocysteinemic group). 
After informed consent patients were randomized to daily multivitamin supplementation (5 mg folic 
acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin) or placebo and were followed for 2.5 years. 
End-points were objectively diagnosed recurrent deep-vein thrombosis or pulmonary embolism. 
A total of 701 patients were enrolled (360 in the hyper- and 341 in the normohomocysteinemic 
group). The number of recurrent events of venous thrombosis was 43 out of 353 in the vitamin 
group (54/1000yr) and 50 out of 348 in the placebo group (64/1000yr ). The hazard ratio associated 
with vitamin treatment was 0.84 (95% CI 0.56 to 1.26): 1.14 (95% CI 0.65 to 1.98) in the 
hyperhomocysteinemic group and 0.58 (95% CI 0.31 to 1.07) in the normohomocysteinemic group. 
The results of our study do not show that homocysteine lowering by B-vitamin supplementation 
prevents recurrent venous thrombosis.  
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Introduction 
Plasma homocysteine levels are associated with an increased risk of deep-vein 
thrombosis and pulmonary embolism. Up to now 24 case-control studies have 
been published with an overall relative risk for venous thrombosis of 1.60 (95% 
CI 1.10 to 2.34) for a 5 µmol/l higher homocysteine level1. Moreover, three 
prospective studies showed an overall relative risk for venous thrombosis of 
1.27 (95% CI 1.01 to 1.59) for a difference of 5 umol/l1. Recent meta-analyses 
on the effect of the MTHFR 677TT genotype on cardiovascular disease (2) and 
venous thrombosis1,3 showed a modest increase in risk, supporting a 
hypothesis that homocysteine levels are causally related to thrombotic risk. 
Elevated homocysteine levels can be easily treated with B-vitamin 
supplementation (folic acid, vitamin B6 and vitamin B12). Daily use of folic acid 
gives a 25% reduction in homocysteine levels even at low doses of 0.5 mg4,5. 
The question is whether lowering of homocysteine by use of B-vitamin 
supplementation also lowers the risk for venous thrombosis. 
In the VITRO (VItamins and ThROmbosis) study, the primary aim was to 
investigate the effect of a combination preparation of 5 mg folic acid, 50 mg of 
pyridoxine and 0.4 mg cyanocobalamin in the secondary prevention of deep-
vein thrombosis and pulmonary embolism in patients with a first event of 
venous thrombosis and hyperhomocysteinemia in a randomized, double-blind 
and placebo controlled setting. 
A secondary aim was to study the effect of vitamin supplementation in patients 
with a first event of venous thrombosis and a ‘normal’ homocysteine 
concentration in an identical setting6. 
Patients and methods 
Study participants 
Patients were selected through anticoagulation clinics in The Netherlands. 
Anticoagulation clinics monitor the anticoagulant treatment of virtually all 
patients in well-defined geographical areas. Participating anticoagulation clinics 
asked all patients with a first venous thrombosis to donate a blood sample for 
homocysteine determination. Patients with a homocysteine plasma 
concentration in the top quartile of its distribution in the general population 
(homocysteine ≥12.6 µmol/l)7 and who met the entry criteria formed the 
hyperhomocysteinemic group. Enrollment started in March 1996. Because the 
rate of inclusion was lower than expected, the trial was extended in 1998 with 
the Thrombosis Centers of Milan and Vienna who included patients with 
homocysteine above the 75th percentile based on reference population of the 
respective countries (homocysteine ≥10.6 µmol/l in Milano and homocysteine 
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≥8.5 µmol/l in women and ≥10.4 µmol/l in men in Vienna). The latest patient 
was included in May 2001. Parallel to the study in the hyperhomocysteinemic 
group we performed a study in the normohomocysteinemic group, which was 
done only in the Netherlands. During the study there was no folate fortification 
in these three countries. 
For all patients who consented in donating blood for homocysteine 
measurement information was retrieved from the general practitioner or 
specialist of the patients about the diagnosis and circumstances in which 
patients developed their thrombosis. Patients were eligible when they had 
objectively confirmed proximal deep-vein thrombosis or pulmonary embolism in 
absence of major risk factors (major surgery, known malignant disease, 
pregnancy and puerperium or immobility for more than three weeks), are aged 
between 20 to 80 years at time of diagnosis and without obligatory use of 
vitamin B. When patients met all entry criteria, they were asked to give their 
informed consent in accordance with the current revision of the declaration of 
Helsinki (2000). 
Randomization and intervention 
Eligible patients were randomized to receive high-dose multivitamin daily or 
identicalappearing placebo. The high-dose multivitamin capsule contained 
5 mg folic acid, 0.4 mg cyanocobalamin and 50 mg pyridoxine. The 
randomization was performed with 4 and 6 random permuted blocks, stratified 
by homocysteine status (hyperversus normohomocysteinemia), sex and by 
anticoagulation clinic or study center. The study medication was based on an 
earlier study on the homocysteine lowering effects of B-vitamins5. The 
medication was tested for stability for the duration of the trial through 
determination of the vitamin contents of the vitamin capsules. The ranges 
found during 42 months were 0.4-0.5 mg/capsule for cobalamin, 48.3-
59.1 mg/capsule for pyridoxine and 5.1-7.0 mg/capsule for folic acid. Placebo’s 
were made for this trial and capsules were identical for both placebo and 
vitamins. 
Duration of treatment and follow-up was intended for 2.5 years. Participants 
were seen (after overnight fasting) at the start of the study (before 
randomization) and 3, 6, and 24 months after randomization. Blood was 
collected at each visit, for determination of homocysteine. Patients received 
their study medication at these follow up visits or by mail every 3 or 6 months. 
The participants started with their study medication as soon as they were 
randomized i.e. within the period of anticoagulant treatment in order to achieve 
the homocysteine lowering effect in the vitamin group before the cessation of 
anticoagulant treatment. Compliance of the drugs was monitored by measuring 
homocysteine levels. 
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End-points 
The primary endpoint of the study was recurrent symptomatic DVT or recurrent 
PE. This endpoint was defined as the decision of the treating physician to 
restart anticoagulant medication. The treating physician was not informed 
about study medication or homocysteine concentration. Because it might be 
difficult to make an accurate diagnosis of recurrent deep-vein thrombosis or 
pulmonary embolism because of residual thrombi, we provided a tool for the 
treating physicians to make the diagnosis of recurrent deep-vein thrombosis 
more accurate. In patients with a deep-vein thrombosis of the leg a 
compression ultrasonography (CUS) was done 3 months after the thrombotic 
event. If a residue of the old thrombus was seen on the CUS, the CUS was 
repeated 6 and if necessary 12 months after the thrombosis. In patients with a 
PE, CUS of both legs was performed to exclude a DVT. The ultrasonographies 
were performed in one hospital or institution in every participating center. The 
results of these tests were noted down in a so-called ‘patient passport’, a 
booklet which patients were instructed to take with them if they visited their 
physician with symptoms of a recurrent thrombosis. By using this passport, 
data on residual thrombosis were available, even if the patient visited another 
hospital with complaints of recurrent thrombosis. The recommended definition 
of 'recurrent DVT' was when a previously normal or normalized venous 
segment could not be compressed with CUS, or when there was an increment 
in the diameter of residual thrombus with 4 mm8,9. The diagnosis of recurrent 
PE was according to standard clinical practice. 
Laboratory measurements 
To screen patients with first-time venous thrombosis for hyperhomo-
cysteinemia, homocysteine has to be measured in a large number of patients. 
To avoid homocysteine increase after blood sampling, we used blood collection 
tubes with acidic citrate as anticoagulant10. After entering the intervention study 
blood was taken at 0, 3, 6 and 24 months after start of the study. This blood 
was collected after an overnight fast in EDTA-tubes and directly placed on ice 
and centrifuged within one hour. The total homocysteine concentration in 
EDTA-plasma was measured in one central laboratory (Laboratory of 
Pediatrics and Neurology in Nijmegen) by an automated high-performance 
liquid chromatography method with reverse phase and fluorescent detection 
(Gilson 232-401 sample processor, Spectra Physics 8800 solvent delivery 
system and Spectra Physics LC 304 fluorometer), essentially according to the 
method by Fiskerstrand et al.11, with modifications12. 
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Study size 
Sample size was calculated for the hyperhomocysteinemic group: With 
alpha=0.05 and beta=0.2 and with an expected recurrence rate of 20% in 
patients with idiopathic thrombosis (based on the study of Eichinger et al.13) 
and hyperhomocysteinemia in 2.5 year, and a 50% risk reduction due to the 
vitamin therapy (based on a relative risk of more than two for 
hyperhomocysteinemia7,13 and the assumption that a 90% of those with 
homocysteine levels above the 90th percentile could be reduced to less than 
the 90th percentile with multivitamin treatment5, 155 patients in each treatment 
group were required in the hyperhomocysteinemic group6. It was decided to 
randomize the same number of patients in the normohomocysteinemic group. 
So the intended total sample size was 620. 
Statistics 
We compared the high-dose vitamin group and the placebo group with respect 
to age, sex, type of first event (DVT versus pulmonary embolism), initial 
homocysteine levels for both the hyperhomocysteinemic patients and 
normohomocysteinemic patients respectively. 
Relative risk estimates (hazard ratios) and their 95% confidence intervals (CI) 
were calculated with a Cox proportional hazard model to assess the effects of 
high-dose multivitamin supplementation. Variables included in the model were 
treatment regimen (vitamin versus placebo) and the variables on which the 
randomization was stratified i.e. sex, anticoagulation clinic and initial 
homocysteine levels (hyperhomocysteinemic or normohomocysteinemic). 
The primary analysis was an intention-to-treat analysis starting at the day of 
randomization and a follow-up of 2.5 year. We did an on-treatment analysis 
with restriction of the observation time to the time that patients had reported to 
take their capsules. A second on-treatment analysis was performed by 
stratifying the homocysteine reduction in three categories (more than 50% 
reduction, 50-0% reduction and no reduction in homocysteine level) and 
calculating the hazard ratio for the first two categories compared to no 
homocysteine reduction. 
Because the treatment regimen started while patients were on anticoagulation 
treatment (which has a great influence on the risk of recurrence) we also did an 
analysis without taking in to account the recurrences that occurred before two 
months after cessation of anticoagulation . In all these three models the data of 
randomization (and start of the treatment regimen) was the starting time in the 
Cox model. Finally we used a Cox model with the date of cessation of 
anticoagulation as starting time. 
To assess the role of baseline homocysteine levels as a risk predictor of 
recurrent events we also performed a Cox model with homocysteine as 
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continuous variable (in µmol/l) and age, sex and study medication as 
covariates. 
Results 
The participating anticoagulation clinics screened 4382 patients (Figure 8.1). Of 
these patients, 2000 had a homocysteine plasma concentration ≥12.6 µmol/l 
(75th percentile in a general Dutch population). 1522 of these 2000 patients did 
not meet the entry criteria and 153 refused participation. The remaining 
hyperhomocysteinemic patients (n=325) were randomized in the 
hyperhomocysteinemic group. The Thrombosis Centers of Milan and Vienna 
included an additional 35 patients with homocysteine above the 75th percentile 
based on reference population of the centers. Of the 4382 patients screened in 
the Netherlands 2382 had homocysteine values below 12.6 µmol/l. 1886 
patients did not meet the entry criteria or were randomly excluded and 155 
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Figure 8.1    Study design 
 
The baseline characteristics for the vitamin and placebo groups according to 
their homocysteine level (hyperhomocysteinemic and normohomocysteinemic) 
are shown in Table 8.1. The differences in homocysteine levels between the 
hyperhomocysteinemic and the normohomocysteinemic group based on the 
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homocysteine measurement at time of screening remained high at the start of 
the treatment study. The hyperhomocysteinemic group was slightly older than 
the normohomocysteinemic group and included more men, due to the use of a 
uniform cut-off value. However, the vitamin and placebo groups were very 
similar in both the hyper- and normohomocysteinemic groups. 
 
 















Sex (M/F) 103/74 (58/41%) 105/78 (57/43%) 80/96 (45/55%) 74/91 (45/55%) 
Median age in years (range) 56.4 (18.1-79.9) 57.2 (17.9-79.8) 48.2 (20.2-75.5) 46.3 (19.1-78.5) 
Type first event     
   deep-vein thrombosis 119 (76%) 126 (69%) 97 (55%) 100 (61%) 
   pulmonary embolism 43 (24%) 40 (22%) 60 (34%) 51 (31%) 
   both 15 (8%) 17 (9%) 19 (11%) 14 (8%) 
Median duration of anticoagulation in 
months (range) after randomization 1.6 (0-30) 1.8 (0-30) 1.5 (0-18) 1.6 (0-30) 
Geometric mean baseline 










Geometric mean homocysteine after 












We analyzed the effect of the vitamin/placebo treatment 3 month after start of 
the intervention. These data demonstrated no effect of placebo on the 
homocysteine values, whereas a 46% reduction of homocysteine values could 
be demonstrated in the hyperhomocysteinemic group and a 33% reduction was 
observed in the normohomocysteinemic group. 
During the course of the study, 43 out of 353 (12.2%) patients suffered from a 
recurrent event of venous thrombosis in the multivitamin group and 50 out of 
348 (14.3%) patients had a recurrent venous thrombosis in the placebo group. 
Figure 8.2 shows the recurrent thrombosis cumulative incidence curves of 
patients treated with multivitamins versus those treated with placebo. The 
overall hazard ratio was 0.84 (95% CI 0.56 to 1.26), e.g. a risk reduction of 
16% (95% CI –26 to 44). The hazard ratio associated with vitamin 
supplementation was 1.14 (95% CI 0.65 to 1.98) in the hyperhomocysteinemic 
group and 0.58 (95% CI 0.31 to 1.07) in the normohomocysteinemic group. 
The hazard ratio for men versus women was 1.6 (95% CI 1.05 to 2.45). There 
was no significant effect for the other covariates. 
The results of the on-treatment analysis were similar to the intention to treat 
analysis (Table 8.2). However, when we stratified the homocysteine reduction 
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in three categories (more than 50% reduction, 50-0% reduction and no 
reduction in homocysteine level) we found a hazard ratio of 0.82 (95% CI 0.51 
to 1.32) for a 50-0% reduction and 0.43 (95% CI 0.15 to 1.24) for a more than 
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Figure 8.2 Recurrent thrombosis cumulative incidence in patients treated with multivitamin (       ) 




Because the treatment regimen started while patients were on anticoagulation 
treatment (which has a great influence on the risk of recurrence) we also did an 
analysis after exclusion of early recurrences (during anticoagulant treatment or 
within the first two months after cessation of anticoagulant treatment) (Table 
8.2). This subgroup analysis gave similar risk estimates for the hyper- and 
normohomocysteinemic group. This was also seen in the fourth analysis in 









HR vitamin versus placebob
Intention to treat analysis    
Hyperhomocysteinemic group  26/387 (6.7%)  24/403 (6.0%)  1.14 (0.65 to 1.98) 
Normohomocysteinemicgroup  17/412 (4.1%)  26/373 (7.0%)  0.58 (0.32 to 1.08) 
Overall  43/799 (5.4)%  50/776 (6.4%)  0.84 (0.56 to 1.26) 
On treatment analysis 
   
Hyperhomocysteinemic group  24/338 (7.1%)  22/344 (6.4%)  1.13 (0.63 to 2.02) 
Normohomocysteinemicgroup  16/363 (4.4%)  22/337 (6.5%)  0.65 (0.34 to 1.24) 
Overall  40/702 (5.7%)  44/682 (6.4%)  0.88 (0.57 to 1.36) 
Intention to treat analysis with exclusion of early recurrencesc
Hyperhomocysteinemic group  17/387 (4.4%)  21/403 (5.2%)  0.84 (0.44 to 1.60) 
Normohomocysteinemicgroup  15/412 (3.6%)  20/373 (5.4%)  0.66 (0.34 to 1.30) 
Overall  32/799 (4.0%)  41/775 (5.3%)  0.76 (0.48 to 1.21) 
Intention to treat analysis beginning after cessation of anticoagulation 
Hyperhomocysteinemic group  23/338 (6.8%)  24/347 (6.9%)  0.98 (0.55 to 1.74) 
Normohomocysteinemicgroup  17/379 (4.5%)  24/338 (7.1%)  0.62 (0.33 to 1.15) 
Overall  40/717 (5.6%)  48/685 (7.0%)  0.80 (0.52 to 1.21) 
a number of recurrences,py=person years, ir=annual incidence in %; b HR=hazard ratio (95% CI), 
adjusted for study center, sex and hyper-/normohomocysteinemia; c early recurrences: recurrences 
before two months after cessation of anticoagulation. 
 
 
Although the duration of anticoagulant treatment was similar for the various 
groups, there was a relatively high number of early recurrences in the hyper-
homocysteinemic vitamin group (9 events) compared with the hyperhomo-
cysteinemic placebo group (3 events). In contrast, in the normohomo-
cysteinemic group early recurrences occurred more often in the placebogroup 
(6 events) than in the vitamin group (2 events). 
To assess the role of baseline homocysteine levels as a risk predictor of 
recurrent events we performed a Cox model with homocysteine as continuous 
variable (in µmol/l) and age, sex and study medication as covariates.The 
hazard ratio for recurrence associated with a 5 µmol/l higher homocysteine 
level at baseline was 1.13 (95% CI 1.05 to 1.20). This effect was similar in the 
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placebo group as in the vitamin group. The hazard ratio for a homocysteine 
concentration above the 90th percentile (20.1 µmol/l) was 1.8 (95% CI 1.1 to 
3.2). Homocysteine levels were not associated with early recurrences. 
Discussion 
Our study is the first clinical trial on the effect of B-vitamins in the prevention of 
recurrent venous thrombosis. Our study shows that B-vitamin supplementation 
lowers homocysteine values but it doesn’t show a risk reduction in recurrent 
venous thrombosis. Homocysteine at baseline is a modest risk factor for 
recurrent events. 
The results of our trial showed a difference in effect in the 
hyperhomocysteinemic group compared to the normohomocysteinemic group. 
This difference in effect was contrary to what was expected and could not be 
biologically explained. Therefore we looked for possible explanations for this 
finding. One explanation is that there is an uneven distribution of early 
recurrences during or shortly after discontinuation of anticoagulation. 
These recurrences might be explained by other risk factors (such as cancer) or 
may be the result of a rebound phenomenon14. In fact, these early recurrences 
were not associated with basal homocysteine levels (as were the recurrences 
during follow-up), so the uneven distribution over the various treatment groups 
could be attributed to chance. When we excluded early recurrences, the overall 
risk estimate became 0.76, and the effects in the hyper- and normohomo-
cysteinemic group were quite similar. The same occurs after taking the date of 
anticoagulant cessation as starting point for the survival analysis. Although, 
these analyses are post-hoc analyses, they support that the overall estimate of 
0.84 (95% CI 0.56 to 1.26) is the best summary of the study, despite an initial 
heterogeneity of effect. 
The domain of our trial was idiopathic venous thrombosis. We had very strict 
inclusion criteria (objectively confirmed first event of proximal deep-vein 
thrombosis or pulmonary embolism in absence of major risk factors - major 
surgery, known malignant disease, pregnancy and puerperium or immobility for 
more than three weeks -, are aged between 20 to 80 years at time of diagnosis 
and without obligatory use of B-vitamins). Most of the patients were not eligible 
because thrombosis occurred after surgery, patients were older than 80, had 
cancer or had a recurrent event. For these reasons many patients had to be 
screened in order to include the required number of patients for this study. 
An important point in clinical trials with B-vitamins is the difference achieved in 
homocysteine concentration in the vitamin group and the placebo group. This 
difference was small in a trial in stroke patients in North-America15. In the 
design of our study we opted for a strong homocysteine lowering effect, which 
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was found in a schedule with 5 mg folate, 0.4 mg vitamin B12 and 50 mg 
vitamin B6 5
Furthermore our study was done in an area without food-fortification with folate. 
Therefore, a strong difference in median homocysteine between high-dose 
multivitamin and placebo of 6.3 µmol/l (42%) in the hyperhomocysteinemic 
group and 2.9 µmol/l (30%) in the normohomocysteinemic group was found. 
An on-treatment analysis based on the percentage of reduction showed a trend 
to a risk reduction in subjects with the highest reduction in homocysteine. This 
finding stresses the importance of adequate homocysteine reduction in clinical 
trials with B-vitamins. The dose-response relationship gives also some 
indication that our trial does not completely exclude an effect of vitamin 
supplementation to prevent recurrent venous thrombosis. 
Our study was designed in 1995. For the sample size calculation we assumed 
a risk reduction of 50% that was based on earlier case-control studies and 
especially on a cohort study in patients with first time venous thrombosis with a 
relative risk of 2.7 for recurrent thrombosis in patients in the top-quartile of the 
homocysteine distribution13. Findings from others, after the start of this trial, 
indicated less strong effects of hyperhomocysteinemia on the risk of first 
thrombosis. In a recent metaanalysis we found a relative risk for venous 
thrombosis between 1.27 in prospective and 1.60 in retrospective studies for a 
5 µmol/l increase in homocysteine1. On the basis of a meta-analysis of MTHFR 
677TT genotype the risk associated with a 3 µmol/l increase in homocysteine 
levels was 16% (1,3). So, the main conclusion of our study is that vitamin 
supplementation for treatment of hyperhomocysteinemia does not results in an 
apparent decrease in incidence of recurrent events. A second conclusion is 
that our study has not enough power to detect or rule out a modest risk 
reduction of 10-20% that is expected now on the base of prospective and 
genetic studies. However, the question is whether such a modest risk reduction 
is clinically relevant, because the associated numbers needed to treat are large 
(75-150 /year) In the field of arterial vascular disease 12 studies on the effect of 
vitamin treatment on vascular disease are initiated16 of which three are 
published now15,17,18. None of these trials did show a beneficial effect of vitamin 
supplementation on the incidence of recurrent vascular events. It should be 
noted that in these trials vitamin supplementation was added to standard 
treatment that included generally platelet aggregation inhibitors, cholesterol-
lowering drugs and antihypertensive medication, which is not a standard 
treatment after an event of venous thrombosis. Therefore the effect of vitamin 
supplementation might be different in a trial in patients with venous thrombosis 
compared to trials in cardiovascular patients. 
Our study was a secondary prevention study. This implies that the risk of 
recurrent venous thrombosis was the subject of study, which might be different 
from the risks of first-time venous thrombosis. This is clearly demonstrated by 
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the observation that factor V Leiden - which is a strong risk factor for first-time 
venous thrombosis – is not or only weakly associated with recurrent venous 
thrombosis19. Two prospective studies has been published on the risk for a 
recurrent event of venous thrombosis associated with hyperhomocysteinemia. 
In the first study elevated homocysteine levels (above the 75the percentile) 
were associated with a 2.7-fold increase in risk13. In the second study no 
increased risk was found (hazard ratio 0.9 (95% CI 0.5 to 1.6))19. In our study 
baseline homocysteine concentration is a predictor of recurrent venous 
thrombosis. However, the relative risk is lower than the risk for first time venous 
thrombosis1. 
One of the problems with secondary prevention studies in venous thrombosis is 
the diagnosis of a recurrent event. It could be difficult to distinguish between a 
recurrent event and the persistence of a residual thrombus (especially in DVT). 
To facilitate uniform diagnosis within the study we did repeated ultrasound 
examinations after the first event and provided a ‘patient passport’ with 
information for the treating physician. There was however no central validation 
of the diagnosis, which is a potential limitation of the study. We have chosen for 
the decision of the treating physician to restart anticoagulant treatment as 
defined endpoint, which is in fact the most clinical relevant parameter. 
Several explanations can be given to the observation that baseline 
homocysteine levels are predictive for a recurrent event but homocysteine 
lowering does not result in a decrease in incidence. First, it might be a matter of 
insufficient power of our study to detect small effects. This explanation is 
supported by the post-hoc analyses and the dose-response relationship. 
Second, it can be explained by another factor that is related to homocysteine 
but is not affected by vitamin supplementation. However, based on current 
knowledge there is no evidence to treat patients with venous thrombosis with 
B-vitamins in order to prevent recurrent events.  
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General discussion 
In the studies described in this thesis we address several aspects of 
hyperhomocysteinemia in relation to venous thrombosis.  
After the relationship of elevated homocysteine concentrations and venous 
thrombosis was established by our research group and others in earlier studies 
a main issue is whether lowering of homocysteine concentration might prevent  
recurrence of venous thrombosis (homocysteine can be lowered by the 
treatment with B vitamins, including vitamin B11 (Folic acid), Vitamin B12 and 
Vitamin B6).  
This question is of interest for two reasons. The first reason is to gather more 
insight into the pathophysiology of homocysteine metabolism and the possible 
causal relationship of homocysteine and venous thrombosis. Because 
laboratory- and animal studies have not yet found a definite mechanism of 
action, it is of interest to further elucidate the relationship with data from 
epidemiological, intervention studies. In a randomized trial like ours where 
homocysteine-lowering therapy by B-vitamins was used to study if lowering 
homocysteine values does reduce the incidence of venous thrombosis, such an 
effect would strongly support the causal relationship. The second reason is 
obvious: reducing the incidence of venous thrombosis would benefit the 
patients. The outline of the study named VITRO (VItamins and ThROmbosis) is 
described in chapter 2.  
Before we could start the VITRO trial we had to find a suitable collection 
medium for blood samples for homocysteine determination. The determination 
of homocysteine in EDTA tubes is known to pose problems to epidemiological 
field studies since homocysteine values rise if the samples are not placed onto 
ice immediately. Also in clinical practice the assay may lead to false results as 
a consequence of blood handling errors. We showed that tubes containing 
acidic citrate are a suitable collection medium for determination of 
homocysteine concentrations (chapter 3). This observation made it possible for 
us to use this tube for the intervention study described in chapter 2 and 8, 
where it was necessary to screen a large group of persons (>4000) with 
venous thrombosis, under circumstances where immediate processing of 
samples was not possible. Furthermore we showed that the concentrations 
measured in the acidic citrate tubes highly correlate to the concentrations 
measured in EDTA blood. However, reference values need to be established in 
each laboratory since basic concentrations differ in EDTA blood in comparison 
to acidic citrate blood (Chapter 4). By performing these studies we became 
aware of the lack of standardization procedures in homocysteine determination. 
This implies that homocysteine concentrations or cut-off points from studies 
should be evaluated and compared with caution. Comparison with 
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concentrations measured in other studies or even in individual patients is 
therefore often not possible. 
The study described in chapter 5 deals with the effect of oral anticoagulants on 
homocysteine concentrations. We found no relevant effect of oral 
anticoagulants on homocysteine concentrations. Therefore for the 
interpretation of research studies and in individual patients with thrombosis 
where patients were on anticoagulant at the time of homocysteine 
measurement this treatment does not have to be taken into account. 
When hyperhomocysteinemia is a cause of venous thrombosis, one  expects to 
find an association between homocysteine and components of the clotting 
system. For this reason we studied the endogenous thrombin potential (ETP) to 
seek for an association between the ETP and homocysteine values. The ETP 
is a method to measure the potential to generate thrombin, which is a crucial 
component of the clotting cascade. In patients with inherited risk factors for 
venous thrombosis it has been demonstrated that the ETP might be elevated. 
Therefore we reasoned that when high plasma homocysteine values induce 
thrombosis this phenomenon might be reflected by elevated ETP values. 
However, we did not see any association between the ETP and homocysteine 
levels (Chapter 5).  
Venous thrombosis is common in the elderly. The incidence rises from 25 / 
100,000 / year at the age of 25 to 500 / 100,000 / year over the age of 80. 
Since plasma homocysteine levels increase exponentially with age, 
homocysteine might play an important role in the development of venous 
thrombosis in this age group. Two previous studies have reported on the risk of 
hyperhomocysteinemia and the development of venous thrombosis and the 
relation with age, with conflicting results. We therefore performed a case-
control study among elderly patients to evaluate whether elevated 
homocysteine levels are a risk factor for venous thrombosis in this age group, 
as described in chapter 7. In this study we found that the homocysteine 
concentration in plasma is a risk factor for venous thrombosis in elderly 
individuals, as it is among younger people. Furthermore, we found a graded 
increase in the risk with increasing homocysteine concentrations. The risk 
estimate was similar to those reported in studies in younger patient groups. 
This may imply that the absolute effect of hyperhomocysteinemia is greater 
among the elderly, because the incidence of thrombosis is much higher. 
Finally the results of the VITRO trial are described in chapter 8.  
We observed a small effect (15% reduction of venous thrombosis) which did 
not reach statistical significance. However, the sample size of our study was 
not large enough to rule out a modest beneficial effect of homocysteine 
lowering therapy at this level.   
Since our study was underpowered for a small effect it cannot answer the 
question whether homocysteine is of pathophysiological significance in 
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developing venous thrombosis. In the past years several studies have been 
published which suggested an association between thrombosis and the 
MTHFR C677T mutation. Results are however still conflicting since not all 
studies demonstrate this association. This mutation is associated with higher 
homocysteine values, especially in those with lower vitamin B11 and B12 
levels. Since this mutation is a genetic factor it cannot be influenced by the 
disease itself or surrounding factors. Though the association between MTHFR 
C666T and venous thrombosis is at most weak it suggests a causal relation1-3. 
The second reason – but in fact the most relevant one for patients – for 
designing our study was for clinical purposes. When homocysteine is a cause 
of thrombosis homocysteine treatment by vitamins was expected to reduce the 
incidence of recurrent venous thrombosis.  
This trial was the first randomized trial that evaluated the effect of vitamin 
supplementation on venous thrombosis. There have been randomized studies 
which evaluated vitamin supplementation in arterial thrombosis. One study 
evaluated the effect of folic acid as prevention for re-stenosis after coronary 
angioplasty4,5. The authors found a clearly beneficial effect of the therapy on 
the need of revascularization and on composite vascular endpoints (death, 
non-fatal myocardial infarction and revascularization). A second study, 
however, found no effect of folic acid on composite endpoints in patients with 
stable angina pectoris6. A third randomized trial compared high versus low 
dose multivitamin suppletion in the secondary prevention of ischemic stroke, 
coronary heart disease and death7. In this study, no effect of therapy was found 
on the clinical end-points. 
In our study we found no effect, at least not at a statistical significant level. A 
negative result should always be evaluated in the light of the power of a study. 
In our case the number of events (recurrent venous thrombosis) was lower 
than expected,  especially in the control arm with high homocysteine levels. 
This reduced the power.  
In our trial we found a non-significant 16% reduction of recurrent events. 
Therefore we cannot exclude a modest effect, or the absence of any effect. 
Theoretically a reduction in risk of 25% is to be expected according to 
estimations by Wald et al.1. A trial sufficiently powered to demonstrate such an 
effect would need approximately 4000 patient years in both treatment arms. 
We do not expect that such a study will be performed. If homocysteine lowering 
would indeed reduce recurrence by about 15%, the question would be whether 
this is a clinically relevant reduction that would lead to incorporation of this 
treatment. The recurrence risk after a first event of venous thrombosis in our 
study was about 7% per year. A reduction with 15% would imply that about 100 
patients would need to receive vitamins to prevent one event of thrombosis per 
year.  In chapter 8 we conclude our research project with the statement that 
although multivitamin supplementation seems to be safe and is not expensive, 
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this number needed to treat indicates that vitamin supplementation is not a 
clinically relevant option in the secondary prevention of venous thrombosis, 
even in those with hyperhomocysteinemia.     
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Homocysteine is een aminozuur dat betrokken is bij de methionine 
stofwisseling. Een verhoogde homocysteïne-concentratie in het bloed heeft de 
afgelopen jaren in de belangstelling gestaan als mogelijke oorzaak van 
arteriëel vaatlijden (hartinfarcten, beroertes, etalagebenen), maar ook als 
oorzaak van veneuze trombose (trombosebenen en longembolieën). Er zijn 
verscheidene patiënt-controle onderzoeken verricht waaruit bleek dat het 
homocysteïne bij patiënten die in het verleden een trombosebeen of een 
longembolie hadden gehad, vaker verhoogd was dan bij mensen die nooit een 
veneuze trombose hadden doorgemaakt. Dit heeft geleid tot de gedachte dat 
een verhoogde homocysteïne-concentratie een oorzaak zou zijn van trombose. 
Deze gedachte werd bevestigd met enkele prospectieve onderzoeken, waaruit 
bleek dat ook al vóór de trombose de homocysteïne concentraties in het 
plasma verhoogd waren.  
De resultaten van patiënt-controle onderzoeken niet prospectieve onderzoeken 
bewijzen echter niet dat een verhoogd homocysteïne de oorzaak van trombose 
is. Ook geven zij geen antwoord op de vraag of verlaging van het 
homocysteïnegehalte in het bloed trombose kan voorkomen.  
De belangrijkste vraag in dit proefschrift is daarom of homocysteïne-verlagende 
therapie een tweede trombose voorkomt bij trombosepatienten met een 
verhoogd homocysteïne. Allereerst om de hypothese dat een verhoogd 
homocysteïne oorzaak van thrombose is, te verifiëren klopt. Als immers 
verlaging van het homocysteïne gehalte ook het aantal gevallen van trombose 
verlaagt, zou dat een belangrijke aanwijzing zijn dat homocysteïne inderdaad 
bijdraagt aan het ontstaan van trombose. Als tweede – en voor patiënten 
uiteraard van groter belang – het klinische doel van de studie: als door 
verlaging van het homocysteïne een recidief trombose voorkomen kan worden, 
is dat klinisch zeer relevant. Dit is vooral zo omdat iedere trombose een zeker 
risico op ernstige schade of overlijden met zich brengt, maar ook omdat dan 
voorkomen kan worden dat mensen langdurig bloedverdunners moeten 
gebruiken. Deze middelen hebben immers ook bijwerkingen.  
De onderzoeksvraag hebben we proberen te beantwoorden met behulp van 
een gerandomiseerd onderzoek, de VItaminen en TROmbose studie (VITRO) 
(hoofdstuk 2 en 8). Alvorens het onderzoek te beginnen hebben we eerst 
onderzoek gedaan naar een geschikt buisje om het bloed - noodzakelijk voor 
de homocysteïne bepaling - in te bewaren. De logistiek van het onderzoek 
vereiste een bloedafnamebuis waarin het homocysteïne werd gestabiliseerd. In 
de normaliter gebruikte buizen waaraan EDTA is toegevoegd, stijgt het 
homocysteïnegehalte als de buis niet direct wordt gekoeld tot 0ºC. In hoofdstuk 
3 wordt beschreven dat een bloedafnamebuis waaraan zure citraat is 
toegevoegd, geschikt is om bloed af te nemen voor bepaling van het 
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homocysteïne gehalte. In het onderzoek werd echter een verschil 
waargenomen tussen de homocysteïne concentratie in bloed dat was 
afgenomen in een EDTA buis en bloed dat was afgenomen in een buisje met 
zure citraat. Dit heeft geleid tot het onderzoek dat is beschreven in hoofdstuk 4, 
waarbij dit verschil is gekwantificeerd. Bij dit onderzoek is met verscheidene 
meetmethoden het homocysteïne bepaald om te beoordelen of er verschillen 
werden waargenomen. Dit bleek het geval en we concluderen dat de buis met 
zure citraat een goed afnamemedium is, maar dat referentiewaarden moeten 
worden bepaald afhankelijk van de meetmethode die wordt gebruikt. 
Diverse onderzoeken laten zien dat een verhoogd homocysteïne gehalte in het 
bloed gerelateerd is aan trombose. Daarbij is veelal bloed afgenomen na de 
trombose, waarbij patiënten vaak antistollingsmedicatie gebruikten. Ook voor 
het bepalen van homocysteïne bij de individuele persoon is de realiteit dat die 
patiënt veelal bloedverdunners gebruikt ten tijde van de bloedafname. Daarom 
is het van belang te weten of het gebruik van antistolling de bepaling van het 
homocysteïne al dan niet beïnvloedt. Dit bleek niet het geval (hoofdstuk 5).   
De relatie tussen oorzaak en gevolg is niet opgehelderd als het gaat over een 
verhoogd homocysteïnegehalte in het bloed en de ontwikkeling van trombose. 
Zo is er tot op heden nog geen aannemelijk werkingsmechanisme beschreven 
dat verklaart hoe het homocysteïne in het bloed leidt tot een verhoogde 
stollingsneiging. In hoofdstuk 6 hebben we onderzocht of een verhoogd 
homocysteïnegehalte invloed heeft op de endogene trombinepotentieel (ETP). 
De ETP is een maat voor het vermogen om trombine te genereren. Het 
trombine is de belangrijkste stof bij de vorming van stolsels. Van patiënten met 
een verhoogde stollingsneiging op basis van een erfelijke afwijking is 
beschreven dat de ETP verhoogd is. We redeneerden dat als het 
homocysteïne leidt tot trombose, dit wellicht zou kunnen worden terug-
gevonden in een verhoging van de ETP, zoals bij de erfelijke stollings-
neigingen. Dit zou een aanwijzing zijn voor een directe invloed van het 
homocysteïne in het bloed op de stolling. Wij konden echter geen verschil 
waarnemen in de ETP tussen mensen met een verhoogd en met een normaal 
homocysteïne-gehalte. 
Bij de screening van de deelnemers voor het VITRO onderzoek viel op dat bij 
veel oudere trombosepatiënten verhoogde homocysteïne-gehaltes werden 
vastgesteld. Het is bekend dat het homocysteïne, onder andere door een 
verminderde nierfunctie en een verslechterde vitamine-status, bij oudere 
mensen stijgt. Omdat trombose vaak voorkomt op hoge leeftijd, hebben we 
onderzocht of het homocysteïne invloed heeft op het krijgen van een trombose 
op hoge leeftijd. Dit onderzoek staat beschreven in hoofdstuk 7. In een 
onderzoek met 426 patiënten uit de VITRO studie en 294 controles uit de 
algemene bevolking toonden we aan dat ook bij mensen boven de 65 jaar een 
verhoogd homocysteïnegehalte een risicofactor vormt voor het krijgen van een 
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trombosebeen of longembolie. Omdat in onze interventieonderzoek – hieronder 
beschreven – veel ouderen betrokken waren, is dat een belangrijke 
waarneming.  
Tot slot wordt de VITRO studie beschreven. Hierbij kregen patiënten die recent 
een trombosebeen of een longembolie hadden doorgemaakt door loting 
vitaminen B of een placebo (een pil zonder werkzame stof) toegewezen. Er 
werden twee groepen patiënten geselecteerd, nl. patiënten met een verhoogd 
homocysteïne gehalte in het bloed en patiënten met een normale 
homocysteïne waarde. De patiënten hebben gedurende 2,5 jaar de 
onderzoeksmedicatie gebruikt zonder te weten of zij vitamine B of placebo 
slikten. Nadat het onderzoek was afgerond, is bekeken in welke groep de 
meeste recidief trombosen waren voorgekomen. Het bleek dat in de groep met 
hoge homocysteïne waarden bij het begin van het onderzoek, vitamine B het 
homocysteïne weliswaar deed dalen maar het risico op trombose niet 
verminderde: er was zelfs een stijging van het risico van 13% (hetgeen 
overigens niet meer is dan door toevalsvariatie zou kunnen zijn opgetreden). In 
de groep patiënten met normale homocysteïnegehaltes bij het begin van het 
onderzoek daalde het homocysteïne eveneens en werd een risicoreductie van 
35% op trombose gevonden (eveneens binnen de foutmarges van het 
onderzoek). Voor de totale groep was er een risicoreductie van 16%: 12,2% 
recidief-trombose bij vitamine gebruik en 14,3% recidief-trombose bij placebo 
gebruik. De statistische onzekerheid (uitgedrukt in betrouwbaarheids-
intervallen) van deze risicoschattingen was echter groot, zodat dit onderzoek 
niet definitief kan aantonen of uitsluiten of vitamine therapie helpt. 
Onderzoeken die zijn gepubliceerd in de jaren dat ons onderzoek werd verricht, 
hebben duidelijk gemaakt dat het aantal patiënten dat was geselecteerd in de 
VITRO studie te klein om een klein effect van therapie aan te tonen, dat op 
theoretische gronden niet meer zou kunnen zijn dan een risicoreductie van 15 
tot 20%. Wij zijn bij het begin van onze onderzoek uitgegaan van een groter 
verschil. Nieuw onderzoek met meer patiënten (4000) zijn vereist om onze 
onderzoeksvraag definitief te beantwoorden. Ons onderzoek heeft aangetoond 
dat vitaminetherapie zeker geen groot effect heeft op het optreden van 
recidieven. Gegeven de kans op een recidief trombose (ongeveer 7% per jaar) 
betekent dit dat zelfs wanneer een reductie van ongeveer 15% behaald zou 
kunnen worden met vitamines, 100 mensen een jaar behandeld moeten 
worden om een geval van trombose te voorkomen. Dat betekent dat 
homocysteïne verlagende therapie onvoldoende zal bijdragen aan het 
verminderen van het probleem van trombose en dat andere vormen van 




























Dit proefschrift is niet zonder slag of stoot tot stand gekomen. Ik wil in dit 
dankwoord stilstaan bij allen die deel hebben uitgemaakt bij de totstandkoming 
van dit werk.  
 
Mijn promotor, Prof. Dr. F.R. Rosendaal. Beste Frits, het contact wat we 
hadden was schaars, doch die keren dat we bij elkaar zaten heb ik genoten 
van je buitengewone inzicht in de epidemiologie en je kennis op het gebied van 
het tromboseonderzoek. Deze kwaliteiten waren essentieel bij de opzet van de 
VITRO studie. De snelle, zowel inhoudelijke als taalkundige correcties van de 
manuscripten hebben deze telkens weer verbeterd. Mijn dank voor dit alles. 
 
Mijn copromotor, Dr. G.M.J. Bos. Beste Gerard, Zoals niet iedereen zal weten 
ligt je interesse in de tumorimmunologie, en is het onderzoek wat in dit boekje 
is samengebundeld in het verloop van je carrière een zijspoor geweest. 
Ondanks dat wist je altijd de materie met een enorme spitsheid te benaderen. 
Je zette mij daarbij nogal eens op het verkeerde been. Je stimuleerde mij 
daardoor dieper door te denken.  
Ons contact heeft veel te lijden gehad tijdens dit onderzoek. Toch was dit 
proefschrift zonder jou niet tot stand gekomen. Je weet zelf waarom. Ik denk 
dat ik jou daarom het meeste dank verschuldigd ben. 
 
Mijn copromotor, Dr. M. den Heijer. Beste Martin, dankzij jouw vroegere 
onderzoek werd de basis gelegd voor mijn proefschrift. Tijdens jouw opleiding 
tot internist was er vanzelfsprekend weinig tijd voor intensieve begeleiding van 
mij. Dit is ruimstoots gelukt in de tijd daarna. Ik ben je erg dankbaar voor de tijd 
en mogelijkheden die je hebt gecreëerd voor mij om destijds in Nijmegen te 
werken. Inhoudelijk ben je altijd erg goed op de hoogte geweest van ‘het 
homocysteineonderzoek’ en dus inhoudelijk onmisbaar.   
 
Dr. W.B.J. Gerrits, hematoloog, inmiddels gepensioneerd. Beste Wim, jij was 
mijn dichtstbijzijnde begeleider bij het onderzoek. Voor zowel acute logistieke 
problemen, vaak van financiële aard, of beoordeling van inclusiecriteria voor 
studie kon ik altijd bij je terecht. Maar ook op het meer persoonlijke vlak was dit 
het geval: je was immer beschikbaar voor mentale en, niet te vergeten, 
alimentaire bijstand. Dit heb ik zeer gewaardeerd. 
 
Dr. H.J. Blom. Beste Henk, bedankt voor je enthousiaste wijze van begeleiding. 
Dankzij je positieve kijk op de zaken voelde ik altijd prettig als ik met je had 
gesproken en terugreed vanuit Nijmegen naar Den Haag. Net als Martin ben je 
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natuurlijk zeer goed op de hoogte van wat zich afspeelt op het gebied van 
homocysteineonderzoek. Ik heb van deze kennis van zaken veel profijt gehad.  
 
De referent en promotiecommissie (Prof. dr. H.R. Buller, Prof. dr. A. Algra, Dr. 
H.J. Blom, Prof. dr. A.J. Rabelink en Prof. dr. J.P. Vandenbroecke) voor het 
beoordelen van het manuscript en hun bereidwilligheid zitting te nemen in de 
commissie. 
 
Wilma van Spronzen, in de tijd dat ik ben gestart ben met mijn werkzaamheden 
als arts assistent in Eindhoven heb jij de boel in Den Haag draaiende weten te 
dergelijk onderzoek een zware taak. Desondanks (en met schamele 
begeleiding van mijn kant) heb je dit zeer vakkundig en met veel inzet weten te 
volbrengen. Het doet me deugd dat je hierna zelfs ‘in het onderzoek bent 
blijven hangen’.  
 
Marie Louise Brantberger, mijn steun en toeverlaat in de eerste 
onderzoeksjaren. Inmiddels weer woonachtig in geboorteland Zweden. Jij hebt 
de duizenden poststukken en formulieren doorgenomen en ingevoerd in het 
databasesysteem. Een monnikenwerk. Tevens was je een goed luisterend oor 
(naar ik meen was dit wederzijds). 
 
De afdeling hematologie van het Ziekenhuis Leyenburg. De thuisbasis 
gedurende 5 jaar en de afdeling die het onderzoek heeft mogelijk gemaakt. 
de medewerkers van het laboratorium en het secretariaat. Teveel namen om 
überhaupt wel een idee hadden van wat ik nu precies deed met mijn 
piepschuimen dozen en gekoelde buisjes, heb ik me altijd welkom gevoeld op 
het laboratorium en altijd veel steun ondervonden bij de uitvoering van het 
onderzoek. 
 
De medisch directeuren van de trombosediensten van Den Haag (Dr. E. van 
Meegen), Rotterdam (Dr. P.H. Trienekens), Leiden (Dr. F.J.M. van der Meer), 
Amsterdam (Mw. Dr. L.P. Colly, Mw. Dr. M.G.H. Remkes), Utrecht (Mw. Dr. J 
de Vries-Goldschmeding), Delft (Mw. Dr. den Dolder, Mw. M. Addicks) en 
Amersfoort (Dr. M.M.H. Kramer) voor het faciliteren van het onderzoek en de 
interesse tijdens het verloop van de studie. Dankzij de trombosediensten kon 
deze grote groep van patiënten worden verzameld die anders onbereikbaar 
voor ons was geweest..  
Mijn dank gaat uit naar de hematologen Dr. H.L. Haak en Dr. P.W. Weijermans, 
allen hier te vermelden. Hoewel ik me wel eens af heb gevraagd of jullie 
houden. Voor jou, speciaal als laborant zonder ervaring in het doen van een 
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Vanzelfsprekend alle medewerkers van deze trombosediensten, uiteindelijk zijn 
zij het geweest die al die buizen bloed en formulieren hebben verzameld. En dit 
voor slechts enkele taarten soldij! 
 
Astra/Viatris voor de kostenloze terbeschikkingstelling van de studiemedicatie. 
 
De apothekers Dr. G.E.Th. Ferguson en Dr. P.P.H. Le Brun en alle 
medewerkers van de Apotheek Haagse Ziekenhuizen. Tijdens het VITRO 
onderzoek droegen zij de zorg voor de randomisatie in de studie en het 
verpakken en versturen van de vele potten met studiemedicatie.  
 
Dr. M. Cattaneo (Unit of Hematology and Thrombosis, Ospedale San Paolo, 
Universiteit van Milaan) en Mw. Dr. S. Eichinger (Department of Internal Medicine 
I, Medical University of Vienna, Wenen, Oostenrijk) voor hun bijdrage aan de 
VITRO studie.   
 
Stefanie Vloet, bedankt voor de duizenden bepalingen van het homocysteine.  
 
Martijn Havekes, destijds student. Jij bracht door je enthousiaste 
persoonlijkheid veel leven in de brouwerij en dat konden we wel gebruiken!  
 
De maatschap interne geneeskunde in het huidige Maxima Medisch Centrum, 
in het bijzonder de opleider Dr. H.R. Haak. Beste Harm, bedankt voor je steun.  
 
Al mijn vrienden doch in het speciaal Harm Jaap Smit en Henri de Boer. 
Bedankt voor de immer boeiende en stimulerende conversaties over mijn 
promotie en vele andere zaken. Jullie stonden altijd voor me klaar en dit heb ik 
 
Tiny Wouters, bedankt voor het transformeren van een bundel artikeltjes naar 
een echt boekje. 
 
Uitleg overbodig: mijn zussen Marieke en Christine. Speciale dank aan mijn 
zwager Gerard Horsting voor het kaftontwerp. 
 
Alle bekenden en collegae die direct of indirect een bijdrage hebben geleverd 
aan dit proefschrift. Het zijn er teveel om allen bij naam te noemen. Iedereen 
bedankt! 
 
Er zijn vele mensen genoemd zonder wie dit proefschrift niet af zou zijn 
gekomen. Ik wil eindigen met twee mensen zonder wie ik er niet eens aan 
ten zeerste gewaardeerd.   
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begonnen was, mijn ouders. Lieve pa en ma, jullie hebben mij bijgestaan in lief 
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Curriculum vitae 
De auteur van dit proefschrift werd op 2 mei 1966 in ‘s Hertogenbosch geboren 
en woonde tot 1984 in Helvoirt. In 1984 behaalde hij het eindexamen aan het 
gymnasium “Beekvliet” te Sint Michielsgestel. Dit was tevens het aanvangsjaar 
van de studie geneeskunde in Utrecht. In 1990 behaalde hij het 
doctoraalexamen. Voor aanvang van de co-schappen heeft hij neurologisch 
onderzoek verricht bij Prof. C. Warlow in Edinburgh, Schotland. Het co-schap 
gynaecologie en obstetrie werd gedaan in het Kalafong Ziekenhuis in Pretoria, 
Zuid-Afrika. Nadat in 1994 het artsexamen was behaald, is hij als arts-assistent 
interne geneeskunde werkzaam geweest in het Willem-Alexander Ziekenhuis 
in ’s Hertogenbosch (Dr. P.J. Lestrade). In 1995 werd begonnen met het 
onderzoek dat heeft geleid tot dit proefschrift bij de afdeling Haematologie van 
het Leyenburg Ziekenhuis te Den Haag (Dr. W.B.J. Gerrits en Dr. P.W. 
Wijermans). Vanaf 2000 was hij werkzaam in het Máxima Medisch Centrum te 
Eindhoven. In 2001 startte hij in dit ziekenhuis met de opleiding interne 
geneeskunde (Dr. H.R. Haak). In 2004 werd de opleiding voortgezet in het 
Academisch Ziekenhuis Maastricht (Prof. dr. C.D.A. Stehouwer). In oktober 
2006 is hij begonnen met het aandachtsgebied Immunologie en Allergologie 
(Prof. dr. J.W. Cohen-Tervaert). 
 
